Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria

array:24 ["pii" => "S2387020616301942" "issn" => "23870206" "doi" => "10.1016/j.medcle.2016.05.008" "estado" => "S300" "fechaPublicacion" => "2016-03-18" "aid" => "3498" "copyright" => "Elsevier España, S.L.U.. All rights reserved" "copyrightAnyo" => "2016" "documento" => "article" "crossmark" => 1 "subdocumento" => "pgl" "cita" => "Med Clin. 2016;146:278.e1-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0025775316000099" "issn" => "00257753" "doi" => "10.1016/j.medcli.2015.12.012" "estado" => "S300" "fechaPublicacion" => "2016-03-18" "aid" => "3498" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 1 "subdocumento" => "pgl" "cita" => "Med Clin. 2016;146:278.e1-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 142 "formatos" => array:2 [ "HTML" => 29 "PDF" => 113 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "Conferencia de consenso" "titulo" => "Consenso español para el diagnóstico y tratamiento de la hemoglobinuria paroxística nocturna" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "278.e1" "paginaFinal" => "278.e7" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 3595 "Ancho" => 2500 "Tamanyo" => 655869 ] ] "descripcion" => array:1 [ "es" => "Algoritmo de diagnóstico, seguimiento y tratamiento de la HPN. a Hemograma completo, reticulocitos, lactate dehydrogenase (LDH, «deshidrogenasa láctica»), bilirrubina indirecta, haptoglobina, hemoglobina en plasma, hemoglobinuria, hemosidenuria, vitamina B12, eritropoyetina sérica, hierro, ácido fólico, Coombs directo, creatinina, tasa de filtrado glomerular estimada (eGFR), proteinuria. b Ecodoppler abdominal y cardíaco, resonancia magnética craneal o angiografía mediante tomografía computarizada helicoidal (anual o cambios clínicos). c Evaluar individualmente cada caso. BNP: péptido natriurético tipo B; Hb: hemoglobina; HLA: Human Leukocyte Antigen («antígenos leucocitarios humanos»); HPN: hemoglobinuria paroxística nocturna; HTP: hipertensión pulmonar; IP: insuficiencia pulmonar; IR: insuficiencia renal; IRC: insuficiencia renal crónica; NYHA: New York Heart Association; RMN: resonancia magnética nuclear; SDM: síndrome mielodisplásico." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Ana Villegas, Beatriz Arrizabalaga, Santiago Bonanad, Enrique Colado, Anna Gaya, Ataúlfo González, Isidro Jarque, Ramiro Núñez, Emilio Ojeda, Alberto Orfao, José-María Ribera, Vicente Vicente, Álvaro Urbano-Ispizua" "autores" => array:14 [ 0 => array:2 [ "nombre" => "Ana" "apellidos" => "Villegas" ] 1 => array:2 [ "nombre" => "Beatriz" "apellidos" => "Arrizabalaga" ] 2 => array:2 [ "nombre" => "Santiago" "apellidos" => "Bonanad" ] 3 => array:2 [ "nombre" => "Enrique" "apellidos" => "Colado" ] 4 => array:2 [ "nombre" => "Anna" "apellidos" => "Gaya" ] 5 => array:2 [ "nombre" => "Ataúlfo" "apellidos" => "González" ] 6 => array:2 [ "nombre" => "Isidro" "apellidos" => "Jarque" ] 7 => array:2 [ "nombre" => "Ramiro" "apellidos" => "Núñez" ] 8 => array:2 [ "nombre" => "Emilio" "apellidos" => "Ojeda" ] 9 => array:2 [ "nombre" => "Alberto" "apellidos" => "Orfao" ] 10 => array:2 [ "nombre" => "José-María" "apellidos" => "Ribera" ] 11 => array:2 [ "nombre" => "Vicente" "apellidos" => "Vicente" ] 12 => array:2 [ "nombre" => "Álvaro" "apellidos" => "Urbano-Ispizua" ] 13 => array:1 [ "colaborador" => "Grupo de Trabajo de HPN de la Sociedad Española de Hematología y Hemoterapia" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2387020616301942" "doi" => "10.1016/j.medcle.2016.05.008" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020616301942?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775316000099?idApp=UINPBA00004N" "url" => "/00257753/0000014600000006/v2_201606250036/S0025775316000099/v2_201606250036/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2387020616302091" "issn" => "23870206" "doi" => "10.1016/j.medcle.2016.05.009" "estado" => "S300" "fechaPublicacion" => "2016-03-18" "aid" => "3345" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Med Clin. 2016;146:279-80" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Scientific letter" "titulo" => "Detection of alcohol prior to liver transplant, recurrence or continued use?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "279" "paginaFinal" => "280" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Detección del consumo de alcohol inmediatamente antes del trasplante hepático, ¿recaída o continuidad del consumo?" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Ana Carolina Londoño-Ramirez, Enrique Pérez-Martínez, Carlos J. van-der Hofstadt-Román, Jesús Rodríguez-Marín" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Ana Carolina" "apellidos" => "Londoño-Ramirez" ] 1 => array:2 [ "nombre" => "Enrique" "apellidos" => "Pérez-Martínez" ] 2 => array:2 [ "nombre" => "Carlos J." "apellidos" => "van-der Hofstadt-Román" ] 3 => array:2 [ "nombre" => "Jesús" "apellidos" => "Rodríguez-Marín" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S002577531500353X" "doi" => "10.1016/j.medcli.2015.06.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S002577531500353X?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020616302091?idApp=UINPBA00004N" "url" => "/23870206/0000014600000006/v3_201704140441/S2387020616302091/v3_201704140441/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2387020616301930" "issn" => "23870206" "doi" => "10.1016/j.medcle.2016.05.007" "estado" => "S300" "fechaPublicacion" => "2016-03-18" "aid" => "3428" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Med Clin. 2016;146:273-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "Special article" "titulo" => "Guideline development process checklist" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "273" "paginaFinal" => "277" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Lista de comprobación del proceso de elaboracio¿n de guías de práctica clínica" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2030 "Ancho" => 3007 "Tamanyo" => 462403 ] ] "descripcion" => array:1 [ "en" => "Outline of the clinical practice guidelines development process.The different steps and the participation of the guideline development group members (GDG) are interrelated and are not necessarily sequential. The clinical practice guideline (CPG) panel and support groups (such as, for example, methodologists, health economists, the systematic review team and the administrative support secretariat) work collaboratively and are informed by users and interest groups, usually supervised by a monitoring committee. For example, while deciding how to incorporate interest groups early during the process to select and prioritise the subjects, the GDG also needed to consider that the development of formal relations with interest groups will facilitate effective dissemination and implementation and provide support for updating the CPG. In addition, considerations for the organisation, planning and training cover the entire CPG development project, and measures such as documentation of the methodology used and the decisions taken as well as the consideration of conflicts of interest, need to be present throughout the process. (Translated with permission from Schünemann et al.<a class="elsevierStyleCrossRef" href="#bib0150">1</a>)." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Itziar Etxeandia-Ikobaltzeta, Romina Brignardello-Petersen, Alonso Carrasco-Labra, Pablo Alonso-Coello" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Itziar" "apellidos" => "Etxeandia-Ikobaltzeta" ] 1 => array:2 [ "nombre" => "Romina" "apellidos" => "Brignardello-Petersen" ] 2 => array:2 [ "nombre" => "Alonso" "apellidos" => "Carrasco-Labra" ] 3 => array:2 [ "nombre" => "Pablo" "apellidos" => "Alonso-Coello" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S002577531500593X" "doi" => "10.1016/j.medcli.2015.09.023" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S002577531500593X?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020616301930?idApp=UINPBA00004N" "url" => "/23870206/0000014600000006/v3_201704140441/S2387020616301930/v3_201704140441/en/main.assets" ] "en" => array:21 [ "idiomaDefecto" => true "cabecera" => "Consensus statement" "titulo" => "Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "278.e1" "paginaFinal" => "278.e7" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Ana Villegas, Beatriz Arrizabalaga, Santiago Bonanad, Enrique Colado, Anna Gaya, Ataúlfo González, Isidro Jarque, Ramiro Núñez, Emilio Ojeda, Alberto Orfao, José-María Ribera, Vicente Vicente, Álvaro Urbano-Ispizua" "autores" => array:14 [ 0 => array:4 [ "nombre" => "Ana" "apellidos" => "Villegas" "email" => array:1 [ 0 => "anamaria.villegas@salud.madrid.org" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Beatriz" "apellidos" => "Arrizabalaga" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "Santiago" "apellidos" => "Bonanad" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "Enrique" "apellidos" => "Colado" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "d" "identificador" => "aff0020" ] ] ] 4 => array:3 [ "nombre" => "Anna" "apellidos" => "Gaya" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "e" "identificador" => "aff0025" ] ] ] 5 => array:3 [ "nombre" => "Ataúlfo" "apellidos" => "González" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 6 => array:3 [ "nombre" => "Isidro" "apellidos" => "Jarque" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] 7 => array:3 [ "nombre" => "Ramiro" "apellidos" => "Núñez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "f" "identificador" => "aff0030" ] ] ] 8 => array:3 [ "nombre" => "Emilio" "apellidos" => "Ojeda" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "g" "identificador" => "aff0035" ] ] ] 9 => array:3 [ "nombre" => "Alberto" "apellidos" => "Orfao" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "h" "identificador" => "aff0040" ] ] ] 10 => array:3 [ "nombre" => "José-María" "apellidos" => "Ribera" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "i" "identificador" => "aff0045" ] ] ] 11 => array:3 [ "nombre" => "Vicente" "apellidos" => "Vicente" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "j" "identificador" => "aff0050" ] ] ] 12 => array:3 [ "nombre" => "Álvaro" "apellidos" => "Urbano-Ispizua" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "e" "identificador" => "aff0025" ] ] ] 13 => array:1 [ "colaborador" => "Grupo de Trabajo de HPN de la Sociedad Española de Hematología y Hemoterapia" ] ] "afiliaciones" => array:10 [ 0 => array:3 [ "entidad" => "Servicio de Hematología, Hospital Clínico San Carlos de Madrid, Madrid, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Hematología, Hospital Cruces, Bilbao, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Hematología, Hospital La Fe, Valencia, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Servicio de Hematología y Área de Gestión Clínica de Laboratorio de Medicina, Hospital Universitario Central de Asturias, Oviedo, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Servicio de Hematología, Hospital Clínic, Barcelona, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Servicio de Hematología, Hospital Virgen del Rocío, Sevilla, Spain" "etiqueta" => "f" "identificador" => "aff0030" ] 6 => array:3 [ "entidad" => "Servicio de Hematología, Hospital Puerta de Hierro, Madrid, Spain" "etiqueta" => "g" "identificador" => "aff0035" ] 7 => array:3 [ "entidad" => "Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Spain" "etiqueta" => "h" "identificador" => "aff0040" ] 8 => array:3 [ "entidad" => "Servicio de Hematología Clínica, Instituto Catalán de Oncología-Hospital Germans Trias i Pujol, Badalona, Spain" "etiqueta" => "i" "identificador" => "aff0045" ] 9 => array:3 [ "entidad" => "Servicio de Hematología, Hospital Morales Meseguer, Murcia, Spain" "etiqueta" => "j" "identificador" => "aff0050" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Consenso español para el diagnóstico y tratamiento de la hemoglobinuria paroxística nocturna" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 3596 "Ancho" => 2500 "Tamanyo" => 675375 ] ] "descripcion" => array:1 [ "en" => "Algorithm diagnosis, monitoring and treatment of PNH. aFull, reticulocyte blood count, lactate dehydrogenase (LDH), indirect bilirubin, haptoglobin, plasma haemoglobin, haemoglobinuria, haemosidenuria, vitamin B12, serum erythropoietin, iron, folic acid, direct Coombs, creatinine, estimated glomerular filtration rate (eGFR), proteinuria. bAbdominal and cardiac ecodoppler, cranial MRI or angiography through helical computed tomography (annual or clinical changes). cAssess each case individually. BNP: B-type natriuretic peptide; Hb: haemoglobin; HLA: Human Leucocyte Antigen; PNH: paroxysmal nocturnal haemoglobinuria; PH: pulmonary hypertension; PI: pulmonary insufficiency; RF: renal failure; CRF: chronic renal failure; NYHA: New York Heart Association; NMR: nuclear magnetic resonance; MDS: myelodysplastic syndrome." ] ] ] "textoCompleto" => "IntroductionParoxysmal nocturnal haemoglobinuria (PNH) is a clonal disorder of haematopoietic progenitor cells that originates from the acquired mutation of the phosphatidylinositol glycan group A gene (PIGA-A), located in the short arm of chromosome X.<a class="elsevierStyleCrossRef" href="#bib0135">1</a> As a result of this mutation, the glucosyl phosphatidyl inositol (GPI) anchor group does not synthesise, a necessary action for many membrane proteins to bind to the cell surface. Inside these proteins lies the membrane inhibitor of reactive lysis (MIRL) and the complement decay-accelerating factor DAF (CD55), both physiological inhibitors of complement activation. As a result of this deficiency, erythrocytes are more sensitive to the lytic action of complement, causing haemolysis and platelet activation, among other effects.<a class="elsevierStyleCrossRefs" href="#bib0140">2,3</a>The disease can appear at any age, with a higher incidence rate in the third decade of life; gender distribution is similar.<a class="elsevierStyleCrossRef" href="#bib0140">2</a>Clinically, PNH is characterised by intravascular haemolysis, susceptibility to thrombosis and a variable component of bone marrow failure.<a class="elsevierStyleCrossRef" href="#bib0150">4</a> Today PNH is considered a systemic disease – one which may affect several organs, especially the liver, kidney, central nervous system, lung and/or heart – because of the deficiency of nitric oxide (NO) and thrombotic events.<a class="elsevierStyleCrossRefs" href="#bib0150">4,5</a> Haemoglobinuria, a sign that names the disease, cannot be objectified; only 26% of cases initially show symptoms and 62% at some point throughout the course of the disease.<a class="elsevierStyleCrossRefs" href="#bib0145">3,6</a>Complications are a direct result of intravascular haemolysis and sequestration of NO by free haemoglobin. NO depletion produces peripheral vasoconstriction, occurring with dysphagia, erectile dysfunction, abdominal and chest pain and often with profound fatigue that prevents patients from carrying out a normal life.The most common complications are thromboses, the leading cause of death from PNH (40–67% depending on the type). Thromboses are mainly venous, and can be located in unusual places such as hepatic portal vein, splenic vein and mesenteric vein, inferior vena cava, central nervous system veins, skin veins or central retinal vein, although it should be noted that approximately 15% occur in blood circulation, especially in brain and coronary arteries.<a class="elsevierStyleCrossRefs" href="#bib0165">7–9</a>Pulmonary hypertension and renal failure may also be particularly serious complications of the disease.<a class="elsevierStyleCrossRefs" href="#bib0180">10,11</a> Occasionally, patients develop acute renal failure which is usually reversible but may require dialysis. 65% of patients have chronic renal failure, and severe chronic renal failure (stage 3 or higher) in 21% of cases.<a class="elsevierStyleCrossRef" href="#bib0190">12</a>Pregnancy, raising the risk of thrombosis, complicates the natural course of the disease, causing an increase in maternal-foetal morbidity and mortality. It has been estimated that maternal mortality during pregnancy and the immediate post-partum period is 12–21%.<a class="elsevierStyleCrossRefs" href="#bib0195">13,14</a> There is also risk of miscarriage or premature birth.<a class="elsevierStyleCrossRefs" href="#bib0195">13,14</a>The association with bone marrow failure, especially with aplastic anaemia, is widely recognised in all patients, preceding the diagnosis of PNH in many cases.Until 2007, haemolytic PNH patients were treated mainly with blood transfusions. A great therapeutic advance has been the monoclonal antibody, eculizumab, approved both by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). It was first authorised in Spain for use in adult patients with PNH on June 20, 2007, and in April 2013 the indication was extended to paediatric patients. Significantly, on March 30, 2015 the EMA changed the guideline criteria, to include patients with a high activity of the disease, defined as elevated haemolysis, together with one or more of the clinical symptoms associated with it (asthenia, haemoglobinuria, abdominal pain, dyspnoea, anaemia, thrombosis, dysphagia or erectile dysfunction).Eculizumab is a humanised monoclonal antibody that acts by blocking complement protein C5, preventing terminal complement activation and thus haemolysis.<a class="elsevierStyleCrossRefs" href="#bib0205">15,16</a> The use of eculizumab stabilises the haemoglobin and reduces transfusion requirements and symptoms associated with dysfunction of the smooth muscle, reducing fatigue and significantly improving quality of life.<a class="elsevierStyleCrossRef" href="#bib0215">17</a> It has also been shown to reduce the relative risk of thromboembolism by 85% and the reduction in the frequency of cases treated with anticoagulants for previous occlusive vascular episodes is 94%.<a class="elsevierStyleCrossRef" href="#bib0170">8</a> It also improves pulmonary hypertension and renal failure, especially in the early stages. Likewise, it has been used in women with PNH who are pregnant, with encouraging responses and without risk to the mother or the foetus.<a class="elsevierStyleCrossRefs" href="#bib0195">13,18,19</a> Recently, the largest series of monitored cases of pregnant patients with PNH has been published, demonstrating the safety and efficacy of eculizumab in this group of patients.<a class="elsevierStyleCrossRef" href="#bib0230">20</a>At present, after more than 12 years of treatment, sufficient experience has been collected to confirm that treatment with eculizumab has changed the natural history of PNH. In a disease that had a short life expectancy compared to the general population, with a median survival of 10–15 years from diagnosis, there are data showing that treatment with eculizumab produces a significant increase in life expectancy, and its positive effect in improving the quality of life has been proven; it is medication that has a safe profile and which is generally well tolerated.<a class="elsevierStyleCrossRef" href="#bib0235">21</a> Recently, a group of experts in PNH at a hospital in Leeds in England has published a retrospective study where eculizumab treatment improves the survival of patients with PNH relative to a control group of a healthy population of the same age and sex.<a class="elsevierStyleCrossRef" href="#bib0240">22</a>Due to the rapid pace of advances in knowledge of the disease and its treatment, it has become necessary to standardise and adapt clinical practice guidelines in order to facilitate the monitoring of patients with classical or haemolytic PNH.In order to address this need, the Spanish PNH Working Group was created, sponsored by the Spanish Society of Haematology and Haemotherapy, which published in 2011 in Medicina Clínica a first consensus document for management of PNH.<a class="elsevierStyleCrossRef" href="#bib0245">23</a> New data released later that same year led the group to meet again in November 2011; the results of this meeting included an update of the consensus Guide in May 2012. Given the availability of new evidence a second meeting was held in December 2013 that led to another update of the guidelines in June, 2014.<a class="elsevierStyleCrossRef" href="#bib0250">24</a> In January 2015 the Working Group met again in order to continue updating the document, specifically in regard to the following areas: the indication for the study of PNH populations, detection of the PNH clone by flow cytometry, the monitoring of patients with PNH and treatment of the disease. Prior to the meeting, articles that had been published with new information related to these areas were identified through searches on Medline and Embase. The selection of articles to review was performed according to expert judgement. The classification of selected publications based on levels of evidence was conducted by the Centre of Evidence-Based Medicine, considering at level 1 randomised clinical trials; at level 2, cohort studies; at level 3, and case-control studies, and level 4, series of cases. Due to the idiosyncrasies of PNH, classified as an ultra-rare disease, the degree of recommendation is categorised based on experts’ clinical judgement and experience. Additionally, the update of this document has also considered information concerning the management of the disease in clinical practice recorded in the National and International PNH Registration database (PNH registry). During the meeting the selected evidence was presented and the recommendations contained therein were subsequently debated. In order to establish the degree of consensus for each of the recommendations, attendees expressed their level of agreement by voting, considering accepted recommendations as those where at least 66% of the participants agreed. For the December 2013 meeting, three haematologists who are experts in PNH were invited to attend as external evaluators for the review, discussion and validation of the recommendations proposed in the successive updates of the consensus document.This article exposes the recommendations contained in the group's last meeting (May 2015) in regard to the four areas defined above (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>).<elsevierMultimedia ident="fig0005"></elsevierMultimedia>Indications for the study of paroxysmal nocturnal haemoglobinuria populationsThe diagnosis of the PNH should be performed by flow cytometry. The study of PNH populations is indicated in patients with one or more of the following symptoms:<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005">•Haemolytic anaemia with negative Coombs’ test.</li><li class="elsevierStyleListItem" id="lsti0010">•Haemoglobinuria.</li><li class="elsevierStyleListItem" id="lsti0015">•Unexplained, venous or arterial thrombosis in patients who meet any of the following criteria: young patients, presence of thrombosis in unusual locations (intra-abdominal veins, Budd–Chiari syndrome, brain, skin, etc.), evidence of haemolysis and/or cytopenia.</li><li class="elsevierStyleListItem" id="lsti0020">•Intermittent dysphagia or abdominal pain of unknown aetiology with evidence of haemolysis.</li><li class="elsevierStyleListItem" id="lsti0025">•Medullary aplasia (at diagnosis and annually during monitoring).</li><li class="elsevierStyleListItem" id="lsti0030">•Hypoplastic myelodysplastic syndrome.</li><li class="elsevierStyleListItem" id="lsti0035">•Idiopathic and maintained cytopenias of uncertain significance.</li></ul>PNH clone detection by flow cytometryCurrently, analysis is done by flow cytometry, in addition to screening diagnosis, to monitor and treat the disease (see <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).<elsevierMultimedia ident="tbl0005"></elsevierMultimedia>Sample type and cell populations of interestThe study of PNH populations is done routinely in peripheral blood samples. A deficiency of GPI expression is initially identified in neutrophil granulocytes and monocytes. In cases where the presence of cells with GPI anchored proteins deficiency (PNH clone) have been demonstrated, a study of red cells is carried out in a second step.The analysis of the leucocyte for the detection of PNH populations is the best method available to properly assess the size of the deficient clone in GPI. Lymphocytes, because of their long half-life and variable expression of different GPI proteins, do not constitute an adequate population; whereas monocytes and neutrophils are suitable populations given their number, the correlation between the size of clone between themselves and that they can be easily assessed in parallel. The study in leucocytes is the technique of choice for detecting PNH clones, both for low and high sensitivity studies, and for monitoring patients with PNH clone.<a class="elsevierStyleCrossRefs" href="#bib0255">25,26</a>Markers associated with glycosyl phosphatidyl inositolThere are several ways to create the neutrophilic granulocytes and monocytes selection strategy.<a class="elsevierStyleCrossRef" href="#bib0255">25</a> FLAER is particularly useful for researching the deficit of expression of proteins associated to GPI in these populations, it is a fluorescent derivative of the bacterial toxin aerolysin that binds to GPI in different leucocyte populations, in combination with CD157 markers. Another option is to perform the analysis in these sub-populations with FLAER and CD24 (or CD16) and CD14 markers. If FLAER is not available, an alternative is to use CD157PE markers in combination with CD24 (or CD16) and CD14. The combination of CD45 and CD10 markers facilitates identification of neutrophilic granulocytes, whereas for monocytes CD45 and CD64 markers are used.In the case of detecting deficiencies in expression of proteins associated with GPI in neutrophilic granulocytes or monocytes, carrying out the second step is necessary which consists of evaluating the CD59 in red blood cells. CD59 expression is more informative than CD55 expression and other antigens such as CD58, as they are found in greater numbers on the surface of red blood cells. Although other options can work, using PE-conjugated antibodies for GPI molecules detection is recommended as there is more experience with that process. Simultaneous markers of CD55 and CD59 are not recommended, since they require careful titration of reagents to avoid agglutination between the red blood cells. In the case of performing highly sensitive techniques, using antigens for positive selection of red blood cells is essential, where there is only information of CD235a utility.Combinations of markersFor the above mentioned first and second steps, leucocytes and erythrocytes detection respectively, different combinations of antibodies can be used according to the laboratory's capabilities (see <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). The correct identification of sub-populations and GPI deficient clones can be performed using negative and positive controls or positive controls with different fluorescence intensity for each marker (see <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).Evaluation of patients once the diagnosis of paroxysmal nocturnal haemoglobinuria has been confirmedClinical historyPNH is a systemic disease with multiple clinical manifestations. For this reason, the patient's medical history should be detailed so the presence of the most characteristic symptoms and signs of intravascular haemolysis can be detected, (dark urine, jaundice), anaemia, dysfunction of smooth muscles (severe asthenia, dysphagia, abdominal pain, chest pain and erectile dysfunction) and previous thrombosis (abdominal pain, dyspnoea, neurological deficit and chronic headache among others).Mandatory explorations<ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0040">•Laboratory tests include a complete blood count with haemoglobin, neutrophils, platelets, reticulocytes, biochemical study of lactate dehydrogenase (LDH) direct and indirect bilirubin, haptoglobin, plasma haemoglobin, haemoglobinuria, haemosiderinuria, ferric profile (sideremia, transferrin, saturation index transferrin and ferritin) levels of vitamin B12, folic acid, serum erythropoietin and direct Coombs test. An assessment of renal function through analysing plasma levels of creatinine should also be conducted, creatinine clearance, proteinuria and urinary sediment.</li><li class="elsevierStyleListItem" id="lsti0045">•Bone marrow aspirate to carry out a morphological and iron staining study. To perform a differential diagnosis, including a cytogenetic study is also advisable.</li><li class="elsevierStyleListItem" id="lsti0050">•Bone marrow biopsy if the analytical data suggests a bone marrow aplasia.</li><li class="elsevierStyleListItem" id="lsti0055">•Thrombophilia studies.</li><li class="elsevierStyleListItem" id="lsti0060">•Abdominal ultrasound with Doppler.</li><li class="elsevierStyleListItem" id="lsti0065">•Doppler echocardiography: if there is evidence of pulmonary hypertension a pulmonary CT angiography must be requested.</li><li class="elsevierStyleListItem" id="lsti0070">•Determining proBNP or NT-proBNP.</li><li class="elsevierStyleListItem" id="lsti0075">•Magnetic resonance imaging (MRI) or cranial computed tomography (according to radiological criteria) in case of headache or other neurological symptoms.</li></ul>Other recommended explorationsDepending on each case, performing other examinations that complement those listed above could be considered. In young patients, a Human Leucocyte Antigen (human leucocyte antigens) typing is recommended because of the possibility of an eventual stem cell transplantation. The radiological study by abdominal MRI is useful in assessing the degree of renal and hepatic iron deposit.MonitoringPNH patients require comprehensive monitoring with quarterly analytical reviews and renal function assessments (creatinine, creatinine clearance, sediment and proteinuria) every 6 months. Conducting an assessment of the clonal size by flow cytometry at 6 months of diagnosis is advisable to assess the patient's stability, so that in such a case assessing the quantification of the clone annually can be valued. Annual reassessments, or if changes in clinical or biological behaviour of the disease are observed, are recommended according to the characteristics of each patient by performing thoracic and abdominal MRI, abdominal ultrasound with Doppler and Doppler echocardiography.Treatment of paroxysmal nocturnal haemoglobinuriaThe main objective of PNH treatment should be to reduce haemolysis and minimise the risk of complications given the systemic impact of the disease. Additionally, treatment of PNH may require supportive therapy including transfusions of concentrated red blood cells, folic acid and iron supplements, antithrombotic anticoagulant prophylaxis and treatment of thrombotic complications. Corticosteroids have been widely used for years in the treatment of PNH, however there is no clear evidence of their benefits.One great therapeutic advance has been the approval of the monoclonal antibody eculizumab, which controls haemolysis and the pathophysiological consequences of the disease. The only potentially curative treatment of PNH is allogeneic haematopoietic stem cell. However, despite the best results achieved with this procedure in recent years, it is still associated with high morbidity and mortality and is reserved for highly selected patients, especially those with very severe associated aplastic anaemia.EculizumabIndicationsData supporting the use of eculizumab in PNH patients for any of the following: indications is currently available:<ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0080">a)Patients with chronic intravascular haemolytic anaemia that shows LDH at 1.5 times the upper limit of normal and clinical symptoms due to haemolytic anaemia, which may manifest, among other symptoms, as a significant impact on quality of life.</li><li class="elsevierStyleListItem" id="lsti0085">b)Patients with thrombosis attributable to PNH.</li><li class="elsevierStyleListItem" id="lsti0090">c)Patients with chronic renal failure attributable to PNH or repeated episodes of acute renal failure.</li><li class="elsevierStyleListItem" id="lsti0095">d)Patients with regular transfusional requirement due to haemolysis.</li><li class="elsevierStyleListItem" id="lsti0100">e)Patients with lung failure who have dyspnoea and/or chest pain resulting in a limitation of normal activity (New York Heart Association class III or IV) and/or an established diagnosis of pulmonary hypertension when other causes of it have been excluded.</li><li class="elsevierStyleListItem" id="lsti0105">f)Patients with involvement of smooth muscle who show recurrent episodes of severe pain (abdominal, lumbar or oesophageal spasm with a history of dysphagia) requiring hospitalisation or taking opioid analgesics regularly. Before these patients start treatment with eculizumab other causes must be ruled out.</li><li class="elsevierStyleListItem" id="lsti0110">g)Pregnancy in a patient with PNH involves a high risk of thrombosis for mother and foetus, treatment with eculizumab may prevent these complications. However, it is recommended that its use should be assessed on an individual basis.</li></ul>The EMA recently approved an amendment of the indication criteria for treatment with eculizumab to include patients who have high disease activity, regardless of the history of transfusions. High disease activity is defined as elevated haemolysis together with one or more of associated clinical symptoms: fatigue, haemoglobinuria, abdominal pain, dyspnoea, anaemia, thrombosis, dysphagia and/or erectile dysfunction.PNH registration (M07-001) was used to assess the efficacy of eculizumab in PNH patients without a history of red blood cell transfusions. These patients had high disease activity defined as high haemolysis (LDH≥1.5×LSN) and the presence of one or more associated clinical symptoms; fatigue, haemoglobinuria, abdominal pain, shortness of breath (dyspnoea), anaemia (haemoglobin<10g/dl), severe adverse vascular events (including thrombosis), dysphagia or erectile dysfunction.Vaccination against meningococcus with a conjugate vaccine that includes serotypes A, C, Y and W135, in addition to vaccination against serotype B (Bexero) is mandatory at least 2 weeks before starting treatment with eculizumab.DosageEculizumab is administered intravenously, at a weekly dose of 600mg for 4 weeks. During the fifth week a dose of 900mg is administered and thereafter doses of 900mg are continuously administered approximately every 14 days (between 12 and 16 days). In patients with a body weight of less than 40kg, dosage varies depending on the weight (see <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>).<elsevierMultimedia ident="tbl0010"></elsevierMultimedia>MonitoringEvaluation and monitoring of the treatment is conducted by regular laboratory analysis including complete blood count, reticulocyte count and biochemical study of LDH. Conducting a study every three months is recommended to assess renal function and ferric profile (sideremia, transferrin, IST and ferritin). In case of iron overload, an abdominal MRI should be considered to analyse liver iron deposition, and repeated every 12 months. In addition to these parameters a general, direct Coombs test and an anti-C3 test every 3–6 months should also be conducted.Given the increased susceptibility to meningococcal sepsis in patients receiving eculizumab, prophylactic antibiotic treatment is recommended with oral penicillin at 400mg/12h with the prophylactic antibiotic protocol established for each centre.The possibility of a meningococcal infection not covered by vaccination should always be considered. Such that, in the case a patient being treated with eculizumab shows signs of headache, fever, nausea, stiff neck, back pain, rashes, confusion, muscle pain, sensitivity to light or other symptoms of illness, they should contact their haematologist immediately or the emergency department of their nearest hospital or health centre and show their security card.Criteria for continuityThe benefits of treatment with eculizumab should be reviewed every 6 months according to the patient's clinical and laboratory evolution. Additionally, patients who have not complied with their therapy instructions of that of preventive measures are excluded from treatment. However, before stopping treatment a full assessment of the case and an evaluation of the pros and cons of the decision should be performed.Allogeneic haematopoieticAllogeneic haematopoietic is recommended for patients with PNH and associated severe bone marrow failure that meet the criteria for allogeneic haematopoietic transplantation of the Pethema-GETH group for medullary aplasia.National and international registration of paroxysmal nocturnal haemoglobinuriaPNH registration aims to observe the natural evolution of patients with PNH, and the safety and efficacy of long term treatment with eculizumab. Given the rarity of this disease, centralising the data of patients with PNH in a national and international registration is advisable, so that its management and treatment can be furthered.The profile of patients to include in the register are those with a GPI-deficient clone, those with diagnosis of PNH in any of its variants and that are not in treatment, and patients diagnosed with PNH who are receiving eculizumab.Data collection is done in electronic notebooks through the website (https:<a href="http://www.webcrf.net/pnhregistry">www.webcrf.net/pnhregistry</a>). Questionnaires must be completed at the time of inclusion in the registry and every 6 months. In Spain, the company responsible for its implementation is ICON (PNHregistry@iconplc.com). They can be contacted for information on freephone (0) 80042662000.Conflict of interestThe authors declare no conflict of interest." "textoCompletoSecciones" => array:1 [ "secciones" => array:13 [ 0 => array:3 [ "identificador" => "xres828441" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec824643" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres828440" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec824642" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Indications for the study of paroxysmal nocturnal haemoglobinuria populations" ] 6 => array:3 [ "identificador" => "sec0015" "titulo" => "PNH clone detection by flow cytometry" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0020" "titulo" => "Sample type and cell populations of interest" ] 1 => array:2 [ "identificador" => "sec0025" "titulo" => "Markers associated with glycosyl phosphatidyl inositol" ] 2 => array:2 [ "identificador" => "sec0030" "titulo" => "Combinations of markers" ] ] ] 7 => array:3 [ "identificador" => "sec0035" "titulo" => "Evaluation of patients once the diagnosis of paroxysmal nocturnal haemoglobinuria has been confirmed" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0040" "titulo" => "Clinical history" ] 1 => array:2 [ "identificador" => "sec0045" "titulo" => "Mandatory explorations" ] 2 => array:2 [ "identificador" => "sec0050" "titulo" => "Other recommended explorations" ] 3 => array:2 [ "identificador" => "sec0055" "titulo" => "Monitoring" ] ] ] 8 => array:3 [ "identificador" => "sec0060" "titulo" => "Treatment of paroxysmal nocturnal haemoglobinuria" "secciones" => array:2 [ 0 => array:3 [ "identificador" => "sec0065" "titulo" => "Eculizumab" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0070" "titulo" => "Indications" ] 1 => array:2 [ "identificador" => "sec0075" "titulo" => "Dosage" ] 2 => array:2 [ "identificador" => "sec0080" "titulo" => "Monitoring" ] 3 => array:2 [ "identificador" => "sec0085" "titulo" => "Criteria for continuity" ] ] ] 1 => array:2 [ "identificador" => "sec0090" "titulo" => "Allogeneic haematopoietic" ] ] ] 9 => array:2 [ "identificador" => "sec0095" "titulo" => "National and international registration of paroxysmal nocturnal haemoglobinuria" ] 10 => array:2 [ "identificador" => "sec0100" "titulo" => "Conflict of interest" ] 11 => array:2 [ "identificador" => "xack278018" "titulo" => "Acknowledgements" ] 12 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2015-09-17" "fechaAceptado" => "2015-12-01" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec824643" "palabras" => array:3 [ 0 => "Paroxysmal nocturnal haemoglobinuria" 1 => "Haematopoietic progenitor cells" 2 => "Mutation" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec824642" "palabras" => array:3 [ 0 => "Hemoglobinuria paroxística nocturna" 1 => "Células progenitoras hematopoyéticas" 2 => "Mutación" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "Paroxysmal nocturnal haemoglobinuria (PNH) is an acquired clonal disorder of the haematopoietic progenitor cells due to a somatic mutation in the X-linked phosphatidylinositol glycan class A gene. The disease is characterised by intravascular haemolytic anaemia, propensity to thromboembolic events and bone marrow failure. Other direct complications of haemolysis include dysphagia, erectile dysfunction, abdominal pain, asthenia and chronic renal failure (65% of patients). The disease appears more often in the third decade of life and there is no sex or age preference. Detection of markers associated with glucosyl phosphatidyl inositol deficit by flow cytometry is currently used in the diagnosis of PNH. For years, transfusions have been the mainstay of therapy for PNH. A breakthrough in treatment has been the approval of the humanised monoclonal antibody eculizumab, which works by blocking the C5 complement protein, preventing its activation and therefore haemolysis. Several studies have confirmed that treatment with eculizumab avoids or decreases the need for transfusions, decreases the probability of thrombosis, improves the associated symptomatology and the quality of life in patients with PNH, showing an increase in survival. Because of rapid advances in the knowledge of the disease and its treatment, it may become necessary to adapt and standardise clinical guidelines for the management of patients with PNH." ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "La hemoglobinuria paroxística nocturna (HPN) es una enfermedad clonal de las células progenitoras hematopoyéticas originada por la mutación adquirida del gen fosfatidil-inositol-glicano del grupo A, situado en el brazo corto del cromosoma X. Se caracteriza por anemia hemolítica intravascular, tendencia a la trombosis y un componente variable de insuficiencia medular. Otras complicaciones derivadas de la hemólisis son disfagia, disfunción eréctil, dolores abdominales, astenia e insuficiencia renal crónica (un 65% de los pacientes). La enfermedad afecta por igual a ambos sexos y puede aparecer a cualquier edad, con una mayor incidencia en la tercera década de la vida. Actualmente, el diagnóstico se basa en la detección de poblaciones celulares con marcadores asociados al déficit de glucosil-fosfatidil-inositol mediante citometría de flujo. Durante años, el pilar terapéutico de la HPN hemolítica era el soporte transfusional. Un gran avance en el tratamiento ha sido la aprobación del anticuerpo monoclonal humanizado eculizumab, que bloquea la proteína C5 del complemento impidiendo su activación, y por tanto, la hemólisis. Diversos estudios han confirmado que el tratamiento con eculizumab evita o disminuye el requerimiento transfusional, reduce la probabilidad de trombosis, mejora la sintomatología asociada y la calidad de vida de los pacientes con HPN, mostrando un aumento de la supervivencia. Este rápido avance en el conocimiento de la enfermedad y su tratamiento hace necesario adaptar y homogeneizar las directrices de actuación clínica en el manejo de pacientes con HPN." ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "Please cite this article as: Villegas A, Arrizabalaga B, Bonanad S, Colado E, Gaya A, González A, et al. Consenso español para el diagnóstico y tratamiento de la hemoglobinuria paroxística nocturna. Med Clin (Barc). 2016;146:278." ] ] "multimedia" => array:3 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 3596 "Ancho" => 2500 "Tamanyo" => 675375 ] ] "descripcion" => array:1 [ "en" => "Algorithm diagnosis, monitoring and treatment of PNH. aFull, reticulocyte blood count, lactate dehydrogenase (LDH), indirect bilirubin, haptoglobin, plasma haemoglobin, haemoglobinuria, haemosidenuria, vitamin B12, serum erythropoietin, iron, folic acid, direct Coombs, creatinine, estimated glomerular filtration rate (eGFR), proteinuria. bAbdominal and cardiac ecodoppler, cranial MRI or angiography through helical computed tomography (annual or clinical changes). cAssess each case individually. BNP: B-type natriuretic peptide; Hb: haemoglobin; HLA: Human Leucocyte Antigen; PNH: paroxysmal nocturnal haemoglobinuria; PH: pulmonary hypertension; PI: pulmonary insufficiency; RF: renal failure; CRF: chronic renal failure; NYHA: New York Heart Association; NMR: nuclear magnetic resonance; MDS: myelodysplastic syndrome." ] ] 1 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Study variable \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Recommendation \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Type of sample \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Peripheral blood \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="2" align="left" valign="top">Populations</td><td class="td" title="table-entry " align="left" valign="top">Step one Neutrophilic granulocytes and monocytes \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Step two Red blood cells \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="3" align="left" valign="top">GPI Markers</td><td class="td" title="table-entry " align="left" valign="top">Step one (granulocytes neutrophils and monocytes): FLAER and CD157 or FLAER, CD24 (or CD16) and CD14 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Alternatively (if FLAER is not available): CD157PE, CD24 (or CD16) and CD14 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Step two (red blood cells): CD59 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">Additional information</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Additional cell identification markers \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">CD45 and CD10 or CD15 for neutrophil granulocytes CD45 and CD64 for monocytes CD235a for red blood cells \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="2" align="left" valign="top">Combinations of markers to study leucocyte<a class="elsevierStyleCrossRef" href="#tblfn0005">a</a></td><td class="td" title="table-entry " align="left" valign="top">5-fluorescence (in a tube): FLAER CD157-PE CD45-PerCP CD64-APC CD10-APCH7 or FLAER CD157-PE CD45-PECy7 CD64-ECD CD10-PECy5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">4-fluorescence (2 in a tubes): FLAER CD157 (or CD24)-PE CD45-PerCP CD10-APC and FLAER CD157 (or CD14)-PE CD45-PerCP CD10-APC or FLAER CD157 (or CD24)-PE CD45-PECy7 CD10-PECy5 FLAER CD157 (or CD14)-PE CD45-PECy7 CD64-PECy5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Combination of markers to study red blood cells \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">CD235a-FITC, CD59-PE (clone of reference: MEM43) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Tests \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Internal (positive and negative populations or with different fluorescence intensity for each marker) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Indications \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Screening diagnostic; monitoring of the disease and its treatment \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1393887.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "Different combinations adapted to different flow cytometers." ] ] ] "descripcion" => array:1 [ "en" => "Identification of deficient cells in glucosyl phosphatidyl inositol (GPI) by flow cytometry in diagnosis of PNH." ] ] 2 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Population \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Initial phase \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Maintenance phase \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Adult patients (≥18 years old) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">600mg per week×4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">900mg in the 5th week; then 900mg every 14±2 days \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top">Paediatric patients with body weight</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">30–<40kg \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">600mg per week×2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">900mg in the 3rd week; then 900mg every two weeks. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">20–<30kg \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">600mg per week×2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">600mg in the 3rd week; then 600mg every two weeks. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">10–<20kg \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">600mg per week×1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">300mg in the 2rd week; then 300mg every two weeks. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">5–<10kg \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">300mg per week×1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">300mg in the 2nd week; then 300mg every three weeks. \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1393886.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Dosage of eculizumab." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:26 [ 0 => array:3 [ "identificador" => "bib0135" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Takeda" 1 => "T. Miyata" 2 => "K. Kawagoe" 3 => "Y. Iida" 4 => "Y. Endo" 5 => "T. Fujita" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Cell" "fecha" => "1993" "volumen" => "73" "paginaInicial" => "703" "paginaFinal" => "711" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8500164" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0140" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Natural history of paroxysmal nocturnal hemoglobinuria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "P. Hillmen" 1 => "S.M. Lewis" 2 => "M. Bessler" 3 => "L. Luzzatto" 4 => "J.V. Dacie" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJM199511093331904" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "1995" "volumen" => "333" "paginaInicial" => "1253" "paginaFinal" => "1258" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7566002" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0145" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnosis and management of paroxysmal nocturnal hemoglobinuria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Parker" 1 => "M. Omine" 2 => "S. Richards" 3 => "J. Nishimura" 4 => "M. Bessler" 5 => "R. Ware" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1182/blood-2005-04-1717" "Revista" => array:6 [ "tituloSerie" => "Blood" "fecha" => "2005" "volumen" => "106" "paginaInicial" => "3699" "paginaFinal" => "3709" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16051736" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0150" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "How I treat paroxysmal nocturnal hemoglobinuria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Brodsky R.A. Brodsky" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1182/blood-2009-03-195966" "Revista" => array:6 [ "tituloSerie" => "Blood" "fecha" => "2009" "volumen" => "113" "paginaInicial" => "6522" "paginaFinal" => "6527" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19372253" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0155" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "R.P. Rother" 1 => "L. Bell" 2 => "P. Hillmen" 3 => "M.T. Gladwin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jama.293.13.1653" "Revista" => array:6 [ "tituloSerie" => "JAMA" "fecha" => "2005" "volumen" => "293" "paginaInicial" => "1653" "paginaFinal" => "1662" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15811985" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0160" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H. Schrezenmeier" 1 => "P. Muus" 2 => "G. Socie" 3 => "J. Szer" 4 => "A. Urbano-Ispizua" 5 => "J.P. Maciejewski" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3324/haematol.2013.093161" "Revista" => array:6 [ "tituloSerie" => "Haematologica" "fecha" => "2014" "volumen" => "99" "paginaInicial" => "922" "paginaFinal" => "929" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24488565" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0165" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C. Hall" 1 => "S. Richards" 2 => "P. Hillmen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1182/blood-2003-01-0009" "Revista" => array:6 [ "tituloSerie" => "Blood" "fecha" => "2003" "volumen" => "102" "paginaInicial" => "3587" "paginaFinal" => "3591" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12893760" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0170" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Hillmen" 1 => "P. Muus" 2 => "U. Duhrsen" 3 => "A.M. Risitano" 4 => "J. Schubert" 5 => "L. Luzzatto" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1182/blood-2007-06-095646" "Revista" => array:6 [ "tituloSerie" => "Blood" "fecha" => "2007" "volumen" => "110" "paginaInicial" => "4123" "paginaFinal" => "4128" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17702897" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0175" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:3 [ "comentario" => "quiz 5105" "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Thrombosis in paroxysmal nocturnal hemoglobinuria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Hill" 1 => "R.J. Kelly" 2 => "P. Hillmen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1182/blood-2012-09-311381" "Revista" => array:6 [ "tituloSerie" => "Blood" "fecha" => "2013" "volumen" => "121" "paginaInicial" => "4985" "paginaFinal" => "4996" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23610373" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0180" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "National Kidney Foundation" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Kidney Dis" "fecha" => "2002" "volumen" => "39" "paginaInicial" => "S1" "paginaFinal" => "S266" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11904577" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0185" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "SEN-SEMFYC consensus document on chronic kidney disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Alcazar" 1 => "M.I. Egocheaga" 2 => "L. Orte" 3 => "J.M. Lobos" 4 => "E. Gonzalez Parra" 5 => "F. Alvarez Guisasola" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Nefrologia" "fecha" => "2008" "volumen" => "28" "paginaInicial" => "273" "paginaFinal" => "282" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18590493" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0190" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Hillmen" 1 => "M. Elebute" 2 => "R. Kelly" 3 => "A. Urbano-Ispizua" 4 => "A. Hill" 5 => "R.P. Rother" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/ajh.21757" "Revista" => array:6 [ "tituloSerie" => "Am J Hematol" "fecha" => "2010" "volumen" => "85" "paginaInicial" => "553" "paginaFinal" => "559" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20658586" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0195" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Kelly" 1 => "L. Arnold" 2 => "S. Richards" 3 => "A. Hill" 4 => "C. Bomken" 5 => "J. Hanley" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2141.2010.08099.x" "Revista" => array:6 [ "tituloSerie" => "Br J Haematol" "fecha" => "2010" "volumen" => "149" "paginaInicial" => "446" "paginaFinal" => "450" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20151973" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0200" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. De Guibert" 1 => "R. Peffault de Latour" 2 => "N. Varoqueaux" 3 => "H. Labussiere" 4 => "B. Rio" 5 => "D. Jaulmes" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3324/haematol.2010.037531" "Revista" => array:6 [ "tituloSerie" => "Haematologica" "fecha" => "2011" "volumen" => "96" "paginaInicial" => "1276" "paginaFinal" => "1283" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21606169" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0205" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Hillmen" 1 => "C. Hall" 2 => "J.C. Marsh" 3 => "M. Elebute" 4 => "M.P. Bombara" 5 => "B.E. Petro" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa031688" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2004" "volumen" => "350" "paginaInicial" => "552" "paginaFinal" => "559" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14762182" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0210" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Hillmen" 1 => "N.S. Young" 2 => "J. Schubert" 3 => "R.A. Brodsky" 4 => "G. Socie" 5 => "P. Muus" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa061648" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2006" "volumen" => "355" "paginaInicial" => "1233" "paginaFinal" => "1243" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16990386" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0215" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.A. Brodsky" 1 => "N.S. Young" 2 => "E. Antonioli" 3 => "A.M. Risitano" 4 => "H. Schrezenmeier" 5 => "J. Schubert" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1182/blood-2007-06-094136" "Revista" => array:6 [ "tituloSerie" => "Blood" "fecha" => "2008" "volumen" => "111" "paginaInicial" => "1840" "paginaFinal" => "1847" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18055865" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0220" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pregnancy in PNH: another eculizumab baby" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Marasca" 1 => "V. Coluccio" 2 => "R. Santachiara" 3 => "G. Leonardi" 4 => "G. Torelli" 5 => "R. Notaro" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2141.2010.08258.x" "Revista" => array:6 [ "tituloSerie" => "Br J Haematol" "fecha" => "2010" "volumen" => "150" "paginaInicial" => "707" "paginaFinal" => "708" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20553271" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0225" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Paroxysmal nocturnal hemoglobinuria (PNH) and pregnancy in the era of eculizumab" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A.V. Danilov" 1 => "H. Smith" 2 => "S. Craigo" 3 => "D.M. Feeney" 4 => "V. Relias" 5 => "K.B. Miller" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.leukres.2008.09.008" "Revista" => array:6 [ "tituloSerie" => "Leuk Res" "fecha" => "2009" "volumen" => "33" "paginaInicial" => "e4" "paginaFinal" => "e5" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18952283" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0230" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.J. Kelly" 1 => "B. Hochsmann" 2 => "J. Szer" 3 => "A. Kulasekararaj" 4 => "S. de Guibert" 5 => "A. Roth" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1502950" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2015" "volumen" => "373" "paginaInicial" => "1032" "paginaFinal" => "1039" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26352814" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0235" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Hillmen" 1 => "P. Muus" 2 => "A. Roth" 3 => "M.O. Elebute" 4 => "A.M. Risitano" 5 => "H. Schrezenmeier" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjh.12347" "Revista" => array:6 [ "tituloSerie" => "Br J Haematol" "fecha" => "2013" "volumen" => "162" "paginaInicial" => "62" "paginaFinal" => "73" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23617322" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0240" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.J. Kelly" 1 => "A. Hill" 2 => "L.M. Arnold" 3 => "G.L. Brooksbank" 4 => "S.J. Richards" 5 => "M. Cullen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1182/blood-2011-02-333997" "Revista" => array:6 [ "tituloSerie" => "Blood" "fecha" => "2011" "volumen" => "117" "paginaInicial" => "6786" "paginaFinal" => "6792" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21460245" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0245" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "[Diagnosis and treatment of nocturnal paroxysmal hemoglobinuria]" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Urbano-Ispizua" 1 => "A. Gaya" 2 => "E. Colado" 3 => "M. Lopez" 4 => "B. Arrizabalaga" 5 => "V. Vicente" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Med Clin (Barc)" "fecha" => "2011" "volumen" => "136" "paginaInicial" => "121" "paginaFinal" => "127" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0250" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Villegas A, Arrizabalaga B, Bonanad S, Colado E, Gaya A, González A, et al. Guía clínica HPN. Consenso español para diagnóstico y tratamiento de Hemoglobinuria Paroxística Nocturna. 2014 [accessed May 2015]. Available from: <a href="http://www.sehh.es/en/documents/guides-and-documents/2605-guias-de-consenso-sobre-diagnostico-y-tratamiento-de-la-hemoglobinuria-paroxistica-nocturna-hpn-actualizacion-2014.html">http://www.sehh.es/en/documents/guides-and-documents/2605-guias-de-consenso-sobre-diagnostico-y-tratamiento-de-la-hemoglobinuria-paroxistica-nocturna-hpn-actualizacion-2014.html</a>" ] ] ] 24 => array:3 [ "identificador" => "bib0255" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.J. Borowitz" 1 => "F.E. Craig" 2 => "J.A. Digiuseppe" 3 => "A.J. Illingworth" 4 => "W. Rosse" 5 => "D.R. Sutherland" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/cyto.b.20525" "Revista" => array:6 [ "tituloSerie" => "Cytometry B Clin Cytom" "fecha" => "2010" "volumen" => "78" "paginaInicial" => "211" "paginaFinal" => "230" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20533382" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0260" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High-sensitivity detection of PNH red blood cells, red cell precursors, and white blood cells" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "D.R. Sutherland" 1 => "A. Illingworth" 2 => "M. Keeney" 3 => "S.J. Richards" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Curr Protoc Cytom" "fecha" => "2015" "volumen" => "72" "paginaInicial" => "6 37 1" "paginaFinal" => "6629" ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack278018" "titulo" => "Acknowledgements" "texto" => "The authors would like to thank Alexion Pharma España for its support in the development of the consensus statement. Editorial services were provided by Ogilvy Healthworld Barcelona and funded by Alexion Pharma España." "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/23870206/0000014600000006/v3_201704140441/S2387020616301942/v3_201704140441/en/main.assets" "Apartado" => array:4 [ "identificador" => "46796" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Consensus statement" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/23870206/0000014600000006/v3_201704140441/S2387020616301942/v3_201704140441/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020616301942?idApp=UINPBA00004N"]

Statistics

Consensus statement

Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria

Consenso español para el diagnóstico y tratamiento de la hemoglobinuria paroxística nocturna

Ana Villegasa,

Corresponding author

anamaria.villegas@salud.madrid.org

Corresponding author.

, Beatriz Arrizabalagab, Santiago Bonanadc, Enrique Coladod, Anna Gayae, Ataúlfo Gonzáleza, Isidro Jarquec, Ramiro Núñezf, Emilio Ojedag, Alberto Orfaoh, José-María Riberai, Vicente Vicentej, Álvaro Urbano-Ispizuae, Grupo de Trabajo de HPN de la Sociedad Española de Hematología y Hemoterapia

a Servicio de Hematología, Hospital Clínico San Carlos de Madrid, Madrid, Spain

b Servicio de Hematología, Hospital Cruces, Bilbao, Spain

c Servicio de Hematología, Hospital La Fe, Valencia, Spain

d Servicio de Hematología y Área de Gestión Clínica de Laboratorio de Medicina, Hospital Universitario Central de Asturias, Oviedo, Spain

e Servicio de Hematología, Hospital Clínic, Barcelona, Spain

f Servicio de Hematología, Hospital Virgen del Rocío, Sevilla, Spain

g Servicio de Hematología, Hospital Puerta de Hierro, Madrid, Spain

h Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Spain

i Servicio de Hematología Clínica, Instituto Catalán de Oncología-Hospital Germans Trias i Pujol, Badalona, Spain

j Servicio de Hematología, Hospital Morales Meseguer, Murcia, Spain

Read

Times
was read the article

Total PDF

Total HTML

Share statistics

 array:24 [
  "pii" => "S2387020616301942"
  "issn" => "23870206"
  "doi" => "10.1016/j.medcle.2016.05.008"
  "estado" => "S300"
  "fechaPublicacion" => "2016-03-18"
  "aid" => "3498"
  "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46;. All rights reserved"
  "copyrightAnyo" => "2016"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "pgl"
  "cita" => "Med Clin. 2016;146:278&#46;e1-7"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "es" => array:19 [
      "pii" => "S0025775316000099"
      "issn" => "00257753"
      "doi" => "10.1016/j.medcli.2015.12.012"
      "estado" => "S300"
      "fechaPublicacion" => "2016-03-18"
      "aid" => "3498"
      "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46;"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "pgl"
      "cita" => "Med Clin. 2016;146:278&#46;e1-7"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:2 [
        "total" => 142
        "formatos" => array:2 [
          "HTML" => 29
          "PDF" => 113
        ]
      ]
      "es" => array:13 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Conferencia de consenso</span>"
        "titulo" => "Consenso espa&#241;ol para el diagn&#243;stico y tratamiento de la hemoglobinuria parox&#237;stica nocturna"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "278&#46;e1"
            "paginaFinal" => "278&#46;e7"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0005"
            "etiqueta" => "Figura 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 3595
                "Ancho" => 2500
                "Tamanyo" => 655869
              ]
            ]
            "descripcion" => array:1 [
              "es" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Algoritmo de diagn&#243;stico&#44; seguimiento y tratamiento de la HPN&#46;</p> <p id="spar0020" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleSup">a</span> Hemograma completo&#44; reticulocitos&#44; <span class="elsevierStyleItalic">lactate dehydrogenase</span> &#40;LDH&#44; &#171;deshidrogenasa l&#225;ctica&#187;&#41;&#44; bilirrubina indirecta&#44; haptoglobina&#44; hemoglobina en plasma&#44; hemoglobinuria&#44; hemosidenuria&#44; vitamina B12&#44; eritropoyetina s&#233;rica&#44; hierro&#44; &#225;cido f&#243;lico&#44; Coombs directo&#44; creatinina&#44; tasa de filtrado glomerular estimada &#40;eGFR&#41;&#44; proteinuria&#46; <span class="elsevierStyleSup">b</span> Ecodoppler abdominal y card&#237;aco&#44; resonancia magn&#233;tica craneal o angiograf&#237;a mediante tomograf&#237;a computarizada helicoidal &#40;anual o cambios cl&#237;nicos&#41;&#46; <span class="elsevierStyleSup">c</span> Evaluar individualmente cada caso&#46;</p> <p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">BNP&#58; p&#233;ptido natriur&#233;tico tipo B&#59; Hb&#58; hemoglobina&#59; HLA&#58; <span class="elsevierStyleItalic">Human Leukocyte Antigen</span> &#40;&#171;ant&#237;genos leucocitarios humanos&#187;&#41;&#59; HPN&#58; hemoglobinuria parox&#237;stica nocturna&#59; HTP&#58; hipertensi&#243;n pulmonar&#59; IP&#58; insuficiencia pulmonar&#59; IR&#58; insuficiencia renal&#59; IRC&#58; insuficiencia renal cr&#243;nica&#59; NYHA&#58; <span class="elsevierStyleItalic">New York Heart Association&#59;</span> RMN&#58; resonancia magn&#233;tica nuclear&#59; SDM&#58; s&#237;ndrome mielodispl&#225;sico&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Ana Villegas, Beatriz Arrizabalaga, Santiago Bonanad, Enrique Colado, Anna Gaya, Ata&#250;lfo Gonz&#225;lez, Isidro Jarque, Ramiro N&#250;&#241;ez, Emilio Ojeda, Alberto Orfao, Jos&#233;-Mar&#237;a Ribera, Vicente Vicente, &#193;lvaro Urbano-Ispizua"
            "autores" => array:14 [
              0 => array:2 [
                "nombre" => "Ana"
                "apellidos" => "Villegas"
              ]
              1 => array:2 [
                "nombre" => "Beatriz"
                "apellidos" => "Arrizabalaga"
              ]
              2 => array:2 [
                "nombre" => "Santiago"
                "apellidos" => "Bonanad"
              ]
              3 => array:2 [
                "nombre" => "Enrique"
                "apellidos" => "Colado"
              ]
              4 => array:2 [
                "nombre" => "Anna"
                "apellidos" => "Gaya"
              ]
              5 => array:2 [
                "nombre" => "Ata&#250;lfo"
                "apellidos" => "Gonz&#225;lez"
              ]
              6 => array:2 [
                "nombre" => "Isidro"
                "apellidos" => "Jarque"
              ]
              7 => array:2 [
                "nombre" => "Ramiro"
                "apellidos" => "N&#250;&#241;ez"
              ]
              8 => array:2 [
                "nombre" => "Emilio"
                "apellidos" => "Ojeda"
              ]
              9 => array:2 [
                "nombre" => "Alberto"
                "apellidos" => "Orfao"
              ]
              10 => array:2 [
                "nombre" => "Jos&#233;-Mar&#237;a"
                "apellidos" => "Ribera"
              ]
              11 => array:2 [
                "nombre" => "Vicente"
                "apellidos" => "Vicente"
              ]
              12 => array:2 [
                "nombre" => "&#193;lvaro"
                "apellidos" => "Urbano-Ispizua"
              ]
              13 => array:1 [
                "colaborador" => "Grupo de Trabajo de HPN de la Sociedad Espa&#241;ola de Hematolog&#237;a y Hemoterapia"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2387020616301942"
          "doi" => "10.1016/j.medcle.2016.05.008"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020616301942?idApp=UINPBA00004N"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775316000099?idApp=UINPBA00004N"
      "url" => "/00257753/0000014600000006/v2_201606250036/S0025775316000099/v2_201606250036/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S2387020616302091"
    "issn" => "23870206"
    "doi" => "10.1016/j.medcle.2016.05.009"
    "estado" => "S300"
    "fechaPublicacion" => "2016-03-18"
    "aid" => "3345"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46;"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "cita" => "Med Clin. 2016;146:279-80"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Scientific letter</span>"
      "titulo" => "Detection of alcohol prior to liver transplant&#44; recurrence or continued use&#63;"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "279"
          "paginaFinal" => "280"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Detecci&#243;n del consumo de alcohol inmediatamente antes del trasplante hep&#225;tico&#44; &#191;reca&#237;da o continuidad del consumo&#63;"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Ana Carolina Londo&#241;o-Ramirez, Enrique P&#233;rez-Mart&#237;nez, Carlos J&#46; van-der Hofstadt-Rom&#225;n, Jes&#250;s Rodr&#237;guez-Mar&#237;n"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "Ana Carolina"
              "apellidos" => "Londo&#241;o-Ramirez"
            ]
            1 => array:2 [
              "nombre" => "Enrique"
              "apellidos" => "P&#233;rez-Mart&#237;nez"
            ]
            2 => array:2 [
              "nombre" => "Carlos J&#46;"
              "apellidos" => "van-der Hofstadt-Rom&#225;n"
            ]
            3 => array:2 [
              "nombre" => "Jes&#250;s"
              "apellidos" => "Rodr&#237;guez-Mar&#237;n"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S002577531500353X"
        "doi" => "10.1016/j.medcli.2015.06.005"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S002577531500353X?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020616302091?idApp=UINPBA00004N"
    "url" => "/23870206/0000014600000006/v3_201704140441/S2387020616302091/v3_201704140441/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S2387020616301930"
    "issn" => "23870206"
    "doi" => "10.1016/j.medcle.2016.05.007"
    "estado" => "S300"
    "fechaPublicacion" => "2016-03-18"
    "aid" => "3428"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46;"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "sco"
    "cita" => "Med Clin. 2016;146:273-7"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Special article</span>"
      "titulo" => "Guideline development process checklist"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "273"
          "paginaFinal" => "277"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Lista de comprobaci&#243;n del proceso de elaboracio¿n de gu&#237;as de pr&#225;ctica cl&#237;nica"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Fig&#46; 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 2030
              "Ancho" => 3007
              "Tamanyo" => 462403
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Outline of the clinical practice guidelines development process&#46;The different steps and the participation of the guideline development group members &#40;GDG&#41; are interrelated and are not necessarily sequential&#46; The clinical practice guideline &#40;CPG&#41; panel and support groups &#40;such as&#44; for example&#44; methodologists&#44; health economists&#44; the systematic review team and the administrative support secretariat&#41; work collaboratively and are informed by users and interest groups&#44; usually supervised by a monitoring committee&#46; For example&#44; while deciding how to incorporate interest groups early during the process to select and prioritise the subjects&#44; the GDG also needed to consider that the development of formal relations with interest groups will facilitate effective dissemination and implementation and provide support for updating the CPG&#46; In addition&#44; considerations for the organisation&#44; planning and training cover the entire CPG development project&#44; and measures such as documentation of the methodology used and the decisions taken as well as the consideration of conflicts of interest&#44; need to be present throughout the process&#46; &#40;Translated with permission from Sch&#252;nemann et al&#46;<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">1</span></a>&#41;&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Itziar Etxeandia-Ikobaltzeta, Romina Brignardello-Petersen, Alonso Carrasco-Labra, Pablo Alonso-Coello"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "Itziar"
              "apellidos" => "Etxeandia-Ikobaltzeta"
            ]
            1 => array:2 [
              "nombre" => "Romina"
              "apellidos" => "Brignardello-Petersen"
            ]
            2 => array:2 [
              "nombre" => "Alonso"
              "apellidos" => "Carrasco-Labra"
            ]
            3 => array:2 [
              "nombre" => "Pablo"
              "apellidos" => "Alonso-Coello"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S002577531500593X"
        "doi" => "10.1016/j.medcli.2015.09.023"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S002577531500593X?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020616301930?idApp=UINPBA00004N"
    "url" => "/23870206/0000014600000006/v3_201704140441/S2387020616301930/v3_201704140441/en/main.assets"
  ]
  "en" => array:21 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Consensus statement</span>"
    "titulo" => "Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "278&#46;e1"
        "paginaFinal" => "278&#46;e7"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Ana Villegas, Beatriz Arrizabalaga, Santiago Bonanad, Enrique Colado, Anna Gaya, Ata&#250;lfo Gonz&#225;lez, Isidro Jarque, Ramiro N&#250;&#241;ez, Emilio Ojeda, Alberto Orfao, Jos&#233;-Mar&#237;a Ribera, Vicente Vicente, &#193;lvaro Urbano-Ispizua"
        "autores" => array:14 [
          0 => array:4 [
            "nombre" => "Ana"
            "apellidos" => "Villegas"
            "email" => array:1 [
              0 => "anamaria&#46;villegas&#64;salud&#46;madrid&#46;org"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Beatriz"
            "apellidos" => "Arrizabalaga"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Santiago"
            "apellidos" => "Bonanad"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Enrique"
            "apellidos" => "Colado"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Anna"
            "apellidos" => "Gaya"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "Ata&#250;lfo"
            "apellidos" => "Gonz&#225;lez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "Isidro"
            "apellidos" => "Jarque"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "Ramiro"
            "apellidos" => "N&#250;&#241;ez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "Emilio"
            "apellidos" => "Ojeda"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "aff0035"
              ]
            ]
          ]
          9 => array:3 [
            "nombre" => "Alberto"
            "apellidos" => "Orfao"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "aff0040"
              ]
            ]
          ]
          10 => array:3 [
            "nombre" => "Jos&#233;-Mar&#237;a"
            "apellidos" => "Ribera"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "aff0045"
              ]
            ]
          ]
          11 => array:3 [
            "nombre" => "Vicente"
            "apellidos" => "Vicente"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">j</span>"
                "identificador" => "aff0050"
              ]
            ]
          ]
          12 => array:3 [
            "nombre" => "&#193;lvaro"
            "apellidos" => "Urbano-Ispizua"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          13 => array:1 [
            "colaborador" => "Grupo de Trabajo de HPN de la Sociedad Espa&#241;ola de Hematolog&#237;a y Hemoterapia"
          ]
        ]
        "afiliaciones" => array:10 [
          0 => array:3 [
            "entidad" => "Servicio de Hematolog&#237;a&#44; Hospital Cl&#237;nico San Carlos de Madrid&#44; Madrid&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Hematolog&#237;a&#44; Hospital Cruces&#44; Bilbao&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Servicio de Hematolog&#237;a&#44; Hospital La Fe&#44; Valencia&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Servicio de Hematolog&#237;a y &#193;rea de Gesti&#243;n Cl&#237;nica de Laboratorio de Medicina&#44; Hospital Universitario Central de Asturias&#44; Oviedo&#44; Spain"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Servicio de Hematolog&#237;a&#44; Hospital Cl&#237;nic&#44; Barcelona&#44; Spain"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Servicio de Hematolog&#237;a&#44; Hospital Virgen del Roc&#237;o&#44; Sevilla&#44; Spain"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
          6 => array:3 [
            "entidad" => "Servicio de Hematolog&#237;a&#44; Hospital Puerta de Hierro&#44; Madrid&#44; Spain"
            "etiqueta" => "g"
            "identificador" => "aff0035"
          ]
          7 => array:3 [
            "entidad" => "Servicio de Hematolog&#237;a&#44; Hospital Universitario de Salamanca&#44; Salamanca&#44; Spain"
            "etiqueta" => "h"
            "identificador" => "aff0040"
          ]
          8 => array:3 [
            "entidad" => "Servicio de Hematolog&#237;a Cl&#237;nica&#44; Instituto Catal&#225;n de Oncolog&#237;a-Hospital Germans Trias i Pujol&#44; Badalona&#44; Spain"
            "etiqueta" => "i"
            "identificador" => "aff0045"
          ]
          9 => array:3 [
            "entidad" => "Servicio de Hematolog&#237;a&#44; Hospital Morales Meseguer&#44; Murcia&#44; Spain"
            "etiqueta" => "j"
            "identificador" => "aff0050"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Consenso espa&#241;ol para el diagn&#243;stico y tratamiento de la hemoglobinuria parox&#237;stica nocturna"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Fig&#46; 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 3596
            "Ancho" => 2500
            "Tamanyo" => 675375
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Algorithm diagnosis&#44; monitoring and treatment of PNH&#46; <span class="elsevierStyleSup">a</span>Full&#44; reticulocyte blood count&#44; <span class="elsevierStyleItalic">lactate dehydrogenase</span> &#40;LDH&#41;&#44; indirect bilirubin&#44; haptoglobin&#44; plasma haemoglobin&#44; haemoglobinuria&#44; haemosidenuria&#44; vitamin B12&#44; serum erythropoietin&#44; iron&#44; folic acid&#44; direct Coombs&#44; creatinine&#44; estimated glomerular filtration rate &#40;eGFR&#41;&#44; proteinuria&#46; <span class="elsevierStyleSup">b</span>Abdominal and cardiac ecodoppler&#44; cranial MRI or angiography through helical computed tomography &#40;annual or clinical changes&#41;&#46; <span class="elsevierStyleSup">c</span>Assess each case individually&#46; BNP&#58; B-type natriuretic peptide&#59; Hb&#58; haemoglobin&#59; HLA&#58; <span class="elsevierStyleItalic">Human Leucocyte Antigen</span>&#59; PNH&#58; paroxysmal nocturnal haemoglobinuria&#59; PH&#58; pulmonary hypertension&#59; PI&#58; pulmonary insufficiency&#59; RF&#58; renal failure&#59; CRF&#58; chronic renal failure&#59; NYHA&#58; New York Heart Association&#59; NMR&#58; nuclear magnetic resonance&#59; MDS&#58; myelodysplastic syndrome&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Paroxysmal nocturnal haemoglobinuria &#40;PNH&#41; is a clonal disorder of haematopoietic progenitor cells that originates from the acquired mutation of the phosphatidylinositol glycan group A gene &#40;PIGA-A&#41;&#44; located in the short arm of chromosome X&#46;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">1</span></a> As a result of this mutation&#44; the glucosyl phosphatidyl inositol &#40;GPI&#41; anchor group does not synthesise&#44; a necessary action for many membrane proteins to bind to the cell surface&#46; Inside these proteins lies the membrane inhibitor of reactive lysis &#40;MIRL&#41; and the complement decay-accelerating factor DAF &#40;CD55&#41;&#44; both physiological inhibitors of complement activation&#46; As a result of this deficiency&#44; erythrocytes are more sensitive to the lytic action of complement&#44; causing haemolysis and platelet activation&#44; among other effects&#46;<a class="elsevierStyleCrossRefs" href="#bib0140"><span class="elsevierStyleSup">2&#44;3</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">The disease can appear at any age&#44; with a higher incidence rate in the third decade of life&#59; gender distribution is similar&#46;<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">2</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Clinically&#44; PNH is characterised by intravascular haemolysis&#44; susceptibility to thrombosis and a variable component of bone marrow failure&#46;<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">4</span></a> Today PNH is considered a systemic disease &#8211; one which may affect several organs&#44; especially the liver&#44; kidney&#44; central nervous system&#44; lung and&#47;or heart &#8211; because of the deficiency of nitric oxide &#40;NO&#41; and thrombotic events&#46;<a class="elsevierStyleCrossRefs" href="#bib0150"><span class="elsevierStyleSup">4&#44;5</span></a> Haemoglobinuria&#44; a sign that names the disease&#44; cannot be objectified&#59; only 26&#37; of cases initially show symptoms and 62&#37; at some point throughout the course of the disease&#46;<a class="elsevierStyleCrossRefs" href="#bib0145"><span class="elsevierStyleSup">3&#44;6</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">Complications are a direct result of intravascular haemolysis and sequestration of NO by free haemoglobin&#46; NO depletion produces peripheral vasoconstriction&#44; occurring with dysphagia&#44; erectile dysfunction&#44; abdominal and chest pain and often with profound fatigue that prevents patients from carrying out a normal life&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">The most common complications are thromboses&#44; the leading cause of death from PNH &#40;40&#8211;67&#37; depending on the type&#41;&#46; Thromboses are mainly venous&#44; and can be located in unusual places such as hepatic portal vein&#44; splenic vein and mesenteric vein&#44; inferior vena cava&#44; central nervous system veins&#44; skin veins or central retinal vein&#44; although it should be noted that approximately 15&#37; occur in blood circulation&#44; especially in brain and coronary arteries&#46;<a class="elsevierStyleCrossRefs" href="#bib0165"><span class="elsevierStyleSup">7&#8211;9</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">Pulmonary hypertension and renal failure may also be particularly serious complications of the disease&#46;<a class="elsevierStyleCrossRefs" href="#bib0180"><span class="elsevierStyleSup">10&#44;11</span></a> Occasionally&#44; patients develop acute renal failure which is usually reversible but may require dialysis&#46; 65&#37; of patients have chronic renal failure&#44; and severe chronic renal failure &#40;stage 3 or higher&#41; in 21&#37; of cases&#46;<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">12</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">Pregnancy&#44; raising the risk of thrombosis&#44; complicates the natural course of the disease&#44; causing an increase in maternal-foetal morbidity and mortality&#46; It has been estimated that maternal mortality during pregnancy and the immediate post-partum period is 12&#8211;21&#37;&#46;<a class="elsevierStyleCrossRefs" href="#bib0195"><span class="elsevierStyleSup">13&#44;14</span></a> There is also risk of miscarriage or premature birth&#46;<a class="elsevierStyleCrossRefs" href="#bib0195"><span class="elsevierStyleSup">13&#44;14</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">The association with bone marrow failure&#44; especially with aplastic anaemia&#44; is widely recognised in all patients&#44; preceding the diagnosis of PNH in many cases&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">Until 2007&#44; haemolytic PNH patients were treated mainly with blood transfusions&#46; A great therapeutic advance has been the monoclonal antibody&#44; eculizumab&#44; approved both by the Food and Drug Administration &#40;FDA&#41; and the European Medicines Agency &#40;EMA&#41;&#46; It was first authorised in Spain for use in adult patients with PNH on June 20&#44; 2007&#44; and in April 2013 the indication was extended to paediatric patients&#46; Significantly&#44; on March 30&#44; 2015 the EMA changed the guideline criteria&#44; to include patients with a high activity of the disease&#44; defined as elevated haemolysis&#44; together with one or more of the clinical symptoms associated with it &#40;asthenia&#44; haemoglobinuria&#44; abdominal pain&#44; dyspnoea&#44; anaemia&#44; thrombosis&#44; dysphagia or erectile dysfunction&#41;&#46;</p><p id="par0050" class="elsevierStylePara elsevierViewall">Eculizumab is a humanised monoclonal antibody that acts by blocking complement protein C5&#44; preventing terminal complement activation and thus haemolysis&#46;<a class="elsevierStyleCrossRefs" href="#bib0205"><span class="elsevierStyleSup">15&#44;16</span></a> The use of eculizumab stabilises the haemoglobin and reduces transfusion requirements and symptoms associated with dysfunction of the smooth muscle&#44; reducing fatigue and significantly improving quality of life&#46;<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">17</span></a> It has also been shown to reduce the relative risk of thromboembolism by 85&#37; and the reduction in the frequency of cases treated with anticoagulants for previous occlusive vascular episodes is 94&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">8</span></a> It also improves pulmonary hypertension and renal failure&#44; especially in the early stages&#46; Likewise&#44; it has been used in women with PNH who are pregnant&#44; with encouraging responses and without risk to the mother or the foetus&#46;<a class="elsevierStyleCrossRefs" href="#bib0195"><span class="elsevierStyleSup">13&#44;18&#44;19</span></a> Recently&#44; the largest series of monitored cases of pregnant patients with PNH has been published&#44; demonstrating the safety and efficacy of eculizumab in this group of patients&#46;<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">20</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">At present&#44; after more than 12 years of treatment&#44; sufficient experience has been collected to confirm that treatment with eculizumab has changed the natural history of PNH&#46; In a disease that had a short life expectancy compared to the general population&#44; with a median survival of 10&#8211;15 years from diagnosis&#44; there are data showing that treatment with eculizumab produces a significant increase in life expectancy&#44; and its positive effect in improving the quality of life has been proven&#59; it is medication that has a safe profile and which is generally well tolerated&#46;<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">21</span></a> Recently&#44; a group of experts in PNH at a hospital in Leeds in England has published a retrospective study where eculizumab treatment improves the survival of patients with PNH relative to a control group of a healthy population of the same age and sex&#46;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">22</span></a></p><p id="par0060" class="elsevierStylePara elsevierViewall">Due to the rapid pace of advances in knowledge of the disease and its treatment&#44; it has become necessary to standardise and adapt clinical practice guidelines in order to facilitate the monitoring of patients with classical or haemolytic PNH&#46;</p><p id="par0065" class="elsevierStylePara elsevierViewall">In order to address this need&#44; the Spanish PNH Working Group was created&#44; sponsored by the Spanish Society of Haematology and Haemotherapy&#44; which published in 2011 in <span class="elsevierStyleItalic">Medicina Cl&#237;nica</span> a first consensus document for management of PNH&#46;<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">23</span></a> New data released later that same year led the group to meet again in November 2011&#59; the results of this meeting included an update of the consensus Guide in May 2012&#46; Given the availability of new evidence a second meeting was held in December 2013 that led to another update of the guidelines in June&#44; 2014&#46;<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">24</span></a> In January 2015 the Working Group met again in order to continue updating the document&#44; specifically in regard to the following areas&#58; the indication for the study of PNH populations&#44; detection of the PNH clone by flow cytometry&#44; the monitoring of patients with PNH and treatment of the disease&#46; Prior to the meeting&#44; articles that had been published with new information related to these areas were identified through searches on Medline and Embase&#46; The selection of articles to review was performed according to expert judgement&#46; The classification of selected publications based on levels of evidence was conducted by the Centre of Evidence-Based Medicine&#44; considering at level 1 randomised clinical trials&#59; at level 2&#44; cohort studies&#59; at level 3&#44; and case-control studies&#44; and level 4&#44; series of cases&#46; Due to the idiosyncrasies of PNH&#44; classified as an ultra-rare disease&#44; the degree of recommendation is categorised based on experts&#8217; clinical judgement and experience&#46; Additionally&#44; the update of this document has also considered information concerning the management of the disease in clinical practice recorded in the National and International PNH Registration database &#40;PNH registry&#41;&#46; During the meeting the selected evidence was presented and the recommendations contained therein were subsequently debated&#46; In order to establish the degree of consensus for each of the recommendations&#44; attendees expressed their level of agreement by voting&#44; considering accepted recommendations as those where at least 66&#37; of the participants agreed&#46; For the December 2013 meeting&#44; three haematologists who are experts in PNH were invited to attend as external evaluators for the review&#44; discussion and validation of the recommendations proposed in the successive updates of the consensus document&#46;</p><p id="par0070" class="elsevierStylePara elsevierViewall">This article exposes the recommendations contained in the group&#39;s last meeting &#40;May 2015&#41; in regard to the four areas defined above &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Indications for the study of paroxysmal nocturnal haemoglobinuria populations</span><p id="par0075" class="elsevierStylePara elsevierViewall">The diagnosis of the PNH should be performed by flow cytometry&#46; The study of PNH populations is indicated in patients with one or more of the following symptoms&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">&#8226;</span><p id="par0080" class="elsevierStylePara elsevierViewall">Haemolytic anaemia with negative Coombs&#8217; test&#46;</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">&#8226;</span><p id="par0085" class="elsevierStylePara elsevierViewall">Haemoglobinuria&#46;</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">&#8226;</span><p id="par0090" class="elsevierStylePara elsevierViewall">Unexplained&#44; venous or arterial thrombosis in patients who meet any of the following criteria&#58; young patients&#44; presence of thrombosis in unusual locations &#40;intra-abdominal veins&#44; Budd&#8211;Chiari syndrome&#44; brain&#44; skin&#44; etc&#46;&#41;&#44; evidence of haemolysis and&#47;or cytopenia&#46;</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">&#8226;</span><p id="par0095" class="elsevierStylePara elsevierViewall">Intermittent dysphagia or abdominal pain of unknown aetiology with evidence of haemolysis&#46;</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">&#8226;</span><p id="par0100" class="elsevierStylePara elsevierViewall">Medullary aplasia &#40;at diagnosis and annually during monitoring&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">&#8226;</span><p id="par0105" class="elsevierStylePara elsevierViewall">Hypoplastic myelodysplastic syndrome&#46;</p></li><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">&#8226;</span><p id="par0110" class="elsevierStylePara elsevierViewall">Idiopathic and maintained cytopenias of uncertain significance&#46;</p></li></ul></p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">PNH clone detection by flow cytometry</span><p id="par0115" class="elsevierStylePara elsevierViewall">Currently&#44; analysis is done by flow cytometry&#44; in addition to screening diagnosis&#44; to monitor and treat the disease &#40;see <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Sample type and cell populations of interest</span><p id="par0120" class="elsevierStylePara elsevierViewall">The study of PNH populations is done routinely in peripheral blood samples&#46; A deficiency of GPI expression is initially identified in neutrophil granulocytes and monocytes&#46; In cases where the presence of cells with GPI anchored proteins deficiency &#40;PNH clone&#41; have been demonstrated&#44; a study of red cells is carried out in a second step&#46;</p><p id="par0125" class="elsevierStylePara elsevierViewall">The analysis of the leucocyte for the detection of PNH populations is the best method available to properly assess the size of the deficient clone in GPI&#46; Lymphocytes&#44; because of their long half-life and variable expression of different GPI proteins&#44; do not constitute an adequate population&#59; whereas monocytes and neutrophils are suitable populations given their number&#44; the correlation between the size of clone between themselves and that they can be easily assessed in parallel&#46; The study in leucocytes is the technique of choice for detecting PNH clones&#44; both for low and high sensitivity studies&#44; and for monitoring patients with PNH clone&#46;<a class="elsevierStyleCrossRefs" href="#bib0255"><span class="elsevierStyleSup">25&#44;26</span></a></p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Markers associated with glycosyl phosphatidyl inositol</span><p id="par0130" class="elsevierStylePara elsevierViewall">There are several ways to create the neutrophilic granulocytes and monocytes selection strategy&#46;<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">25</span></a> FLAER is particularly useful for researching the deficit of expression of proteins associated to GPI in these populations&#44; it is a fluorescent derivative of the bacterial toxin aerolysin that binds to GPI in different leucocyte populations&#44; in combination with CD157 markers&#46; Another option is to perform the analysis in these sub-populations with FLAER and CD24 &#40;or CD16&#41; and CD14 markers&#46; If FLAER is not available&#44; an alternative is to use CD157PE markers in combination with CD24 &#40;or CD16&#41; and CD14&#46; The combination of CD45 and CD10 markers facilitates identification of neutrophilic granulocytes&#44; whereas for monocytes CD45 and CD64 markers are used&#46;</p><p id="par0135" class="elsevierStylePara elsevierViewall">In the case of detecting deficiencies in expression of proteins associated with GPI in neutrophilic granulocytes or monocytes&#44; carrying out the second step is necessary which consists of evaluating the CD59 in red blood cells&#46; CD59 expression is more informative than CD55 expression and other antigens such as CD58&#44; as they are found in greater numbers on the surface of red blood cells&#46; Although other options can work&#44; using PE-conjugated antibodies for GPI molecules detection is recommended as there is more experience with that process&#46; Simultaneous markers of CD55 and CD59 are not recommended&#44; since they require careful titration of reagents to avoid agglutination between the red blood cells&#46; In the case of performing highly sensitive techniques&#44; using antigens for positive selection of red blood cells is essential&#44; where there is only information of CD235a utility&#46;</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Combinations of markers</span><p id="par0140" class="elsevierStylePara elsevierViewall">For the above mentioned first and second steps&#44; leucocytes and erythrocytes detection respectively&#44; different combinations of antibodies can be used according to the laboratory&#39;s capabilities &#40;see <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46; The correct identification of sub-populations and GPI deficient clones can be performed using negative and positive controls or positive controls with different fluorescence intensity for each marker &#40;see <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46;</p></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Evaluation of patients once the diagnosis of paroxysmal nocturnal haemoglobinuria has been confirmed</span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Clinical history</span><p id="par0145" class="elsevierStylePara elsevierViewall">PNH is a systemic disease with multiple clinical manifestations&#46; For this reason&#44; the patient&#39;s medical history should be detailed so the presence of the most characteristic symptoms and signs of intravascular haemolysis can be detected&#44; &#40;dark urine&#44; jaundice&#41;&#44; anaemia&#44; dysfunction of smooth muscles &#40;severe asthenia&#44; dysphagia&#44; abdominal pain&#44; chest pain and erectile dysfunction&#41; and previous thrombosis &#40;abdominal pain&#44; dyspnoea&#44; neurological deficit and chronic headache among others&#41;&#46;</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Mandatory explorations</span><p id="par0150" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0040"><span class="elsevierStyleLabel">&#8226;</span><p id="par0155" class="elsevierStylePara elsevierViewall">Laboratory tests include a complete blood count with haemoglobin&#44; neutrophils&#44; platelets&#44; reticulocytes&#44; biochemical study of <span class="elsevierStyleItalic">lactate dehydrogenase</span> &#40;LDH&#41; direct and indirect bilirubin&#44; haptoglobin&#44; plasma haemoglobin&#44; haemoglobinuria&#44; haemosiderinuria&#44; ferric profile &#40;sideremia&#44; transferrin&#44; saturation index transferrin and ferritin&#41; levels of vitamin B12&#44; folic acid&#44; serum erythropoietin and direct Coombs test&#46; An assessment of renal function through analysing plasma levels of creatinine should also be conducted&#44; creatinine clearance&#44; proteinuria and urinary sediment&#46;</p></li><li class="elsevierStyleListItem" id="lsti0045"><span class="elsevierStyleLabel">&#8226;</span><p id="par0160" class="elsevierStylePara elsevierViewall">Bone marrow aspirate to carry out a morphological and iron staining study&#46; To perform a differential diagnosis&#44; including a cytogenetic study is also advisable&#46;</p></li><li class="elsevierStyleListItem" id="lsti0050"><span class="elsevierStyleLabel">&#8226;</span><p id="par0165" class="elsevierStylePara elsevierViewall">Bone marrow biopsy if the analytical data suggests a bone marrow aplasia&#46;</p></li><li class="elsevierStyleListItem" id="lsti0055"><span class="elsevierStyleLabel">&#8226;</span><p id="par0170" class="elsevierStylePara elsevierViewall">Thrombophilia studies&#46;</p></li><li class="elsevierStyleListItem" id="lsti0060"><span class="elsevierStyleLabel">&#8226;</span><p id="par0175" class="elsevierStylePara elsevierViewall">Abdominal ultrasound with Doppler&#46;</p></li><li class="elsevierStyleListItem" id="lsti0065"><span class="elsevierStyleLabel">&#8226;</span><p id="par0180" class="elsevierStylePara elsevierViewall">Doppler echocardiography&#58; if there is evidence of pulmonary hypertension a pulmonary CT angiography must be requested&#46;</p></li><li class="elsevierStyleListItem" id="lsti0070"><span class="elsevierStyleLabel">&#8226;</span><p id="par0185" class="elsevierStylePara elsevierViewall">Determining proBNP or NT-proBNP&#46;</p></li><li class="elsevierStyleListItem" id="lsti0075"><span class="elsevierStyleLabel">&#8226;</span><p id="par0190" class="elsevierStylePara elsevierViewall">Magnetic resonance imaging &#40;MRI&#41; or cranial computed tomography &#40;according to radiological criteria&#41; in case of headache or other neurological symptoms&#46;</p></li></ul></p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Other recommended explorations</span><p id="par0195" class="elsevierStylePara elsevierViewall">Depending on each case&#44; performing other examinations that complement those listed above could be considered&#46; In young patients&#44; a Human Leucocyte Antigen &#40;human leucocyte antigens&#41; typing is recommended because of the possibility of an eventual stem cell transplantation&#46; The radiological study by abdominal MRI is useful in assessing the degree of renal and hepatic iron deposit&#46;</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Monitoring</span><p id="par0200" class="elsevierStylePara elsevierViewall">PNH patients require comprehensive monitoring with quarterly analytical reviews and renal function assessments &#40;creatinine&#44; creatinine clearance&#44; sediment and proteinuria&#41; every 6 months&#46; Conducting an assessment of the clonal size by flow cytometry at 6 months of diagnosis is advisable to assess the patient&#39;s stability&#44; so that in such a case assessing the quantification of the clone annually can be valued&#46; Annual reassessments&#44; or if changes in clinical or biological behaviour of the disease are observed&#44; are recommended according to the characteristics of each patient by performing thoracic and abdominal MRI&#44; abdominal ultrasound with Doppler and Doppler echocardiography&#46;</p></span></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Treatment of paroxysmal nocturnal haemoglobinuria</span><p id="par0205" class="elsevierStylePara elsevierViewall">The main objective of PNH treatment should be to reduce haemolysis and minimise the risk of complications given the systemic impact of the disease&#46; Additionally&#44; treatment of PNH may require supportive therapy including transfusions of concentrated red blood cells&#44; folic acid and iron supplements&#44; antithrombotic anticoagulant prophylaxis and treatment of thrombotic complications&#46; Corticosteroids have been widely used for years in the treatment of PNH&#44; however there is no clear evidence of their benefits&#46;</p><p id="par0210" class="elsevierStylePara elsevierViewall">One great therapeutic advance has been the approval of the monoclonal antibody eculizumab&#44; which controls haemolysis and the pathophysiological consequences of the disease&#46; The only potentially curative treatment of PNH is allogeneic haematopoietic stem cell&#46; However&#44; despite the best results achieved with this procedure in recent years&#44; it is still associated with high morbidity and mortality and is reserved for highly selected patients&#44; especially those with very severe associated aplastic anaemia&#46;</p><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Eculizumab</span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Indications</span><p id="par0215" class="elsevierStylePara elsevierViewall">Data supporting the use of eculizumab in PNH patients for any of the following&#58; indications is currently available&#58;<ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0080"><span class="elsevierStyleLabel">a&#41;</span><p id="par0220" class="elsevierStylePara elsevierViewall">Patients with chronic intravascular haemolytic anaemia that shows LDH at 1&#46;5 times the upper limit of normal and clinical symptoms due to haemolytic anaemia&#44; which may manifest&#44; among other symptoms&#44; as a significant impact on quality of life&#46;</p></li><li class="elsevierStyleListItem" id="lsti0085"><span class="elsevierStyleLabel">b&#41;</span><p id="par0225" class="elsevierStylePara elsevierViewall">Patients with thrombosis attributable to PNH&#46;</p></li><li class="elsevierStyleListItem" id="lsti0090"><span class="elsevierStyleLabel">c&#41;</span><p id="par0230" class="elsevierStylePara elsevierViewall">Patients with chronic renal failure attributable to PNH or repeated episodes of acute renal failure&#46;</p></li><li class="elsevierStyleListItem" id="lsti0095"><span class="elsevierStyleLabel">d&#41;</span><p id="par0235" class="elsevierStylePara elsevierViewall">Patients with regular transfusional requirement due to haemolysis&#46;</p></li><li class="elsevierStyleListItem" id="lsti0100"><span class="elsevierStyleLabel">e&#41;</span><p id="par0240" class="elsevierStylePara elsevierViewall">Patients with lung failure who have dyspnoea and&#47;or chest pain resulting in a limitation of normal activity &#40;New York Heart Association class III or IV&#41; and&#47;or an established diagnosis of pulmonary hypertension when other causes of it have been excluded&#46;</p></li><li class="elsevierStyleListItem" id="lsti0105"><span class="elsevierStyleLabel">f&#41;</span><p id="par0245" class="elsevierStylePara elsevierViewall">Patients with involvement of smooth muscle who show recurrent episodes of severe pain &#40;abdominal&#44; lumbar or oesophageal spasm with a history of dysphagia&#41; requiring hospitalisation or taking opioid analgesics regularly&#46; Before these patients start treatment with eculizumab other causes must be ruled out&#46;</p></li><li class="elsevierStyleListItem" id="lsti0110"><span class="elsevierStyleLabel">g&#41;</span><p id="par0250" class="elsevierStylePara elsevierViewall">Pregnancy in a patient with PNH involves a high risk of thrombosis for mother and foetus&#44; treatment with eculizumab may prevent these complications&#46; However&#44; it is recommended that its use should be assessed on an individual basis&#46;</p></li></ul></p><p id="par0255" class="elsevierStylePara elsevierViewall">The EMA recently approved an amendment of the indication criteria for treatment with eculizumab to include patients who have high disease activity&#44; regardless of the history of transfusions&#46; High disease activity is defined as elevated haemolysis together with one or more of associated clinical symptoms&#58; fatigue&#44; haemoglobinuria&#44; abdominal pain&#44; dyspnoea&#44; anaemia&#44; thrombosis&#44; dysphagia and&#47;or erectile dysfunction&#46;</p><p id="par0260" class="elsevierStylePara elsevierViewall">PNH registration &#40;M07-001&#41; was used to assess the efficacy of eculizumab in PNH patients without a history of red blood cell transfusions&#46; These patients had high disease activity defined as high haemolysis &#40;LDH<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>1&#46;5<span class="elsevierStyleHsp" style=""></span>&#215;<span class="elsevierStyleHsp" style=""></span>LSN&#41; and the presence of one or more associated clinical symptoms&#59; fatigue&#44; haemoglobinuria&#44; abdominal pain&#44; shortness of breath &#40;dyspnoea&#41;&#44; anaemia &#40;haemoglobin<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleHsp" style=""></span>g&#47;dl&#41;&#44; severe adverse vascular events &#40;including thrombosis&#41;&#44; dysphagia or erectile dysfunction&#46;</p><p id="par0265" class="elsevierStylePara elsevierViewall">Vaccination against meningococcus with a conjugate vaccine that includes serotypes A&#44; C&#44; Y and W135&#44; in addition to vaccination against serotype B &#40;Bexero&#41; is mandatory at least 2 weeks before starting treatment with eculizumab&#46;</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Dosage</span><p id="par0270" class="elsevierStylePara elsevierViewall">Eculizumab is administered intravenously&#44; at a weekly dose of 600<span class="elsevierStyleHsp" style=""></span>mg for 4 weeks&#46; During the fifth week a dose of 900<span class="elsevierStyleHsp" style=""></span>mg is administered and thereafter doses of 900<span class="elsevierStyleHsp" style=""></span>mg are continuously administered approximately every 14 days &#40;between 12 and 16 days&#41;&#46; In patients with a body weight of less than 40<span class="elsevierStyleHsp" style=""></span>kg&#44; dosage varies depending on the weight &#40;see <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Monitoring</span><p id="par0275" class="elsevierStylePara elsevierViewall">Evaluation and monitoring of the treatment is conducted by regular laboratory analysis including complete blood count&#44; reticulocyte count and biochemical study of LDH&#46; Conducting a study every three months is recommended to assess renal function and ferric profile &#40;sideremia&#44; transferrin&#44; IST and ferritin&#41;&#46; In case of iron overload&#44; an abdominal MRI should be considered to analyse liver iron deposition&#44; and repeated every 12 months&#46; In addition to these parameters a general&#44; direct Coombs test and an anti-C3 test every 3&#8211;6 months should also be conducted&#46;</p><p id="par0280" class="elsevierStylePara elsevierViewall">Given the increased susceptibility to meningococcal sepsis in patients receiving eculizumab&#44; prophylactic antibiotic treatment is recommended with oral penicillin at 400<span class="elsevierStyleHsp" style=""></span>mg&#47;12<span class="elsevierStyleHsp" style=""></span>h with the prophylactic antibiotic protocol established for each centre&#46;</p><p id="par0285" class="elsevierStylePara elsevierViewall">The possibility of a meningococcal infection not covered by vaccination should always be considered&#46; Such that&#44; in the case a patient being treated with eculizumab shows signs of headache&#44; fever&#44; nausea&#44; stiff neck&#44; back pain&#44; rashes&#44; confusion&#44; muscle pain&#44; sensitivity to light or other symptoms of illness&#44; they should contact their haematologist immediately or the emergency department of their nearest hospital or health centre and show their security card&#46;</p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Criteria for continuity</span><p id="par0290" class="elsevierStylePara elsevierViewall">The benefits of treatment with eculizumab should be reviewed every 6 months according to the patient&#39;s clinical and laboratory evolution&#46; Additionally&#44; patients who have not complied with their therapy instructions of that of preventive measures are excluded from treatment&#46; However&#44; before stopping treatment a full assessment of the case and an evaluation of the pros and cons of the decision should be performed&#46;</p></span></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Allogeneic haematopoietic</span><p id="par0295" class="elsevierStylePara elsevierViewall">Allogeneic haematopoietic is recommended for patients with PNH and associated severe bone marrow failure that meet the criteria for allogeneic haematopoietic transplantation of the Pethema-GETH group for medullary aplasia&#46;</p></span></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">National and international registration of paroxysmal nocturnal haemoglobinuria</span><p id="par0300" class="elsevierStylePara elsevierViewall">PNH registration aims to observe the natural evolution of patients with PNH&#44; and the safety and efficacy of long term treatment with eculizumab&#46; Given the rarity of this disease&#44; centralising the data of patients with PNH in a national and international registration is advisable&#44; so that its management and treatment can be furthered&#46;</p><p id="par0305" class="elsevierStylePara elsevierViewall">The profile of patients to include in the register are those with a GPI-deficient clone&#44; those with diagnosis of PNH in any of its variants and that are not in treatment&#44; and patients diagnosed with PNH who are receiving eculizumab&#46;</p><p id="par0310" class="elsevierStylePara elsevierViewall">Data collection is done in electronic notebooks through the website &#40;https&#58;<a href="http://www.webcrf.net/pnhregistry">www&#46;webcrf&#46;net&#47;pnhregistry</a>&#41;&#46; Questionnaires must be completed at the time of inclusion in the registry and every 6 months&#46; In Spain&#44; the company responsible for its implementation is ICON &#40;PNHregistry&#64;iconplc&#46;com&#41;&#46; They can be contacted for information on freephone &#40;0&#41; 80042662000&#46;</p></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Conflict of interest</span><p id="par0315" class="elsevierStylePara elsevierViewall">The authors declare no conflict of interest&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:13 [
        0 => array:3 [
          "identificador" => "xres828441"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec824643"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres828440"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec824642"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Indications for the study of paroxysmal nocturnal haemoglobinuria populations"
        ]
        6 => array:3 [
          "identificador" => "sec0015"
          "titulo" => "PNH clone detection by flow cytometry"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Sample type and cell populations of interest"
            ]
            1 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Markers associated with glycosyl phosphatidyl inositol"
            ]
            2 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "Combinations of markers"
            ]
          ]
        ]
        7 => array:3 [
          "identificador" => "sec0035"
          "titulo" => "Evaluation of patients once the diagnosis of paroxysmal nocturnal haemoglobinuria has been confirmed"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "Clinical history"
            ]
            1 => array:2 [
              "identificador" => "sec0045"
              "titulo" => "Mandatory explorations"
            ]
            2 => array:2 [
              "identificador" => "sec0050"
              "titulo" => "Other recommended explorations"
            ]
            3 => array:2 [
              "identificador" => "sec0055"
              "titulo" => "Monitoring"
            ]
          ]
        ]
        8 => array:3 [
          "identificador" => "sec0060"
          "titulo" => "Treatment of paroxysmal nocturnal haemoglobinuria"
          "secciones" => array:2 [
            0 => array:3 [
              "identificador" => "sec0065"
              "titulo" => "Eculizumab"
              "secciones" => array:4 [
                0 => array:2 [
                  "identificador" => "sec0070"
                  "titulo" => "Indications"
                ]
                1 => array:2 [
                  "identificador" => "sec0075"
                  "titulo" => "Dosage"
                ]
                2 => array:2 [
                  "identificador" => "sec0080"
                  "titulo" => "Monitoring"
                ]
                3 => array:2 [
                  "identificador" => "sec0085"
                  "titulo" => "Criteria for continuity"
                ]
              ]
            ]
            1 => array:2 [
              "identificador" => "sec0090"
              "titulo" => "Allogeneic haematopoietic"
            ]
          ]
        ]
        9 => array:2 [
          "identificador" => "sec0095"
          "titulo" => "National and international registration of paroxysmal nocturnal haemoglobinuria"
        ]
        10 => array:2 [
          "identificador" => "sec0100"
          "titulo" => "Conflict of interest"
        ]
        11 => array:2 [
          "identificador" => "xack278018"
          "titulo" => "Acknowledgements"
        ]
        12 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2015-09-17"
    "fechaAceptado" => "2015-12-01"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec824643"
          "palabras" => array:3 [
            0 => "Paroxysmal nocturnal haemoglobinuria"
            1 => "Haematopoietic progenitor cells"
            2 => "Mutation"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec824642"
          "palabras" => array:3 [
            0 => "Hemoglobinuria parox&#237;stica nocturna"
            1 => "C&#233;lulas progenitoras hematopoy&#233;ticas"
            2 => "Mutaci&#243;n"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Paroxysmal nocturnal haemoglobinuria &#40;PNH&#41; is an acquired clonal disorder of the haematopoietic progenitor cells due to a somatic mutation in the X-linked <span class="elsevierStyleItalic">phosphatidylinositol glycan class A gene</span>&#46; The disease is characterised by intravascular haemolytic anaemia&#44; propensity to thromboembolic events and bone marrow failure&#46; Other direct complications of haemolysis include dysphagia&#44; erectile dysfunction&#44; abdominal pain&#44; asthenia and chronic renal failure &#40;65&#37; of patients&#41;&#46; The disease appears more often in the third decade of life and there is no sex or age preference&#46; Detection of markers associated with glucosyl phosphatidyl inositol deficit by flow cytometry is currently used in the diagnosis of PNH&#46; For years&#44; transfusions have been the mainstay <span class="elsevierStyleItalic">of therapy</span> for <span class="elsevierStyleItalic">PNH&#46;</span> A breakthrough in treatment has been the approval of the humanised monoclonal antibody eculizumab&#44; which works by blocking the C5 complement protein&#44; preventing its activation and therefore haemolysis&#46; Several studies have confirmed that treatment with eculizumab avoids or decreases the need for transfusions&#44; decreases the probability of thrombosis&#44; improves the associated symptomatology and the quality of life in patients with PNH&#44; showing an increase in survival&#46; Because of rapid advances in the knowledge of the disease and its treatment&#44; it may become necessary to adapt and standardise clinical guidelines for the management of patients with PNH&#46;</p></span>"
      ]
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">La hemoglobinuria parox&#237;stica nocturna &#40;HPN&#41; es una enfermedad clonal de las c&#233;lulas progenitoras hematopoy&#233;ticas originada por la mutaci&#243;n adquirida del gen fosfatidil-inositol-glicano del grupo A&#44; situado en el brazo corto del cromosoma X&#46; Se caracteriza por anemia hemol&#237;tica intravascular&#44; tendencia a la trombosis y un componente variable de insuficiencia medular&#46; Otras complicaciones derivadas de la hem&#243;lisis son disfagia&#44; disfunci&#243;n er&#233;ctil&#44; dolores abdominales&#44; astenia e insuficiencia renal cr&#243;nica &#40;un 65&#37; de los pacientes&#41;&#46; La enfermedad afecta por igual a ambos sexos y puede aparecer a cualquier edad&#44; con una mayor incidencia en la tercera d&#233;cada de la vida&#46; Actualmente&#44; el diagn&#243;stico se basa en la detecci&#243;n de poblaciones celulares con marcadores asociados al d&#233;ficit de glucosil-fosfatidil-inositol mediante citometr&#237;a de flujo&#46; Durante a&#241;os&#44; el pilar terap&#233;utico de la HPN hemol&#237;tica era el soporte transfusional&#46; Un gran avance en el tratamiento ha sido la aprobaci&#243;n del anticuerpo monoclonal humanizado eculizumab&#44; que bloquea la prote&#237;na C5 del complemento impidiendo su activaci&#243;n&#44; y por tanto&#44; la hem&#243;lisis&#46; Diversos estudios han confirmado que el tratamiento con eculizumab evita o disminuye el requerimiento transfusional&#44; reduce la probabilidad de trombosis&#44; mejora la sintomatolog&#237;a asociada y la calidad de vida de los pacientes con HPN&#44; mostrando un aumento de la supervivencia&#46; Este r&#225;pido avance en el conocimiento de la enfermedad y su tratamiento hace necesario adaptar y homogeneizar las directrices de actuaci&#243;n cl&#237;nica en el manejo de pacientes con HPN&#46;</p></span>"
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Please cite this article as&#58; Villegas A&#44; Arrizabalaga B&#44; Bonanad S&#44; Colado E&#44; Gaya A&#44; Gonz&#225;lez A&#44; et al&#46; Consenso espa&#241;ol para el diagn&#243;stico y tratamiento de la hemoglobinuria parox&#237;stica nocturna&#46; Med Clin &#40;Barc&#41;&#46; 2016&#59;146&#58;278&#46;</p>"
      ]
    ]
    "multimedia" => array:3 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Fig&#46; 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 3596
            "Ancho" => 2500
            "Tamanyo" => 675375
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Algorithm diagnosis&#44; monitoring and treatment of PNH&#46; <span class="elsevierStyleSup">a</span>Full&#44; reticulocyte blood count&#44; <span class="elsevierStyleItalic">lactate dehydrogenase</span> &#40;LDH&#41;&#44; indirect bilirubin&#44; haptoglobin&#44; plasma haemoglobin&#44; haemoglobinuria&#44; haemosidenuria&#44; vitamin B12&#44; serum erythropoietin&#44; iron&#44; folic acid&#44; direct Coombs&#44; creatinine&#44; estimated glomerular filtration rate &#40;eGFR&#41;&#44; proteinuria&#46; <span class="elsevierStyleSup">b</span>Abdominal and cardiac ecodoppler&#44; cranial MRI or angiography through helical computed tomography &#40;annual or clinical changes&#41;&#46; <span class="elsevierStyleSup">c</span>Assess each case individually&#46; BNP&#58; B-type natriuretic peptide&#59; Hb&#58; haemoglobin&#59; HLA&#58; <span class="elsevierStyleItalic">Human Leucocyte Antigen</span>&#59; PNH&#58; paroxysmal nocturnal haemoglobinuria&#59; PH&#58; pulmonary hypertension&#59; PI&#58; pulmonary insufficiency&#59; RF&#58; renal failure&#59; CRF&#58; chronic renal failure&#59; NYHA&#58; New York Heart Association&#59; NMR&#58; nuclear magnetic resonance&#59; MDS&#58; myelodysplastic syndrome&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Study variable&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Recommendation&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Type of sample</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Peripheral blood&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Populations</span></td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">Step one</span><br>Neutrophilic granulocytes and monocytes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Step two</span><br>Red blood cells&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="3" align="left" valign="top"><span class="elsevierStyleItalic">GPI Markers</span></td><td class="td" title="table-entry  " align="left" valign="top">Step one &#40;granulocytes neutrophils and monocytes&#41;&#58; FLAER and CD157 or FLAER&#44; CD24 &#40;or CD16&#41; and CD14&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Alternatively &#40;if FLAER is not available&#41;&#58; CD157PE&#44; CD24 &#40;or CD16&#41; and CD14&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Step two &#40;red blood cells&#41;&#58; CD59&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Additional information</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Additional cell identification markers&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">CD45 and CD10 or CD15 for neutrophil granulocytes<br>CD45 and CD64 for monocytes<br>CD235a for red blood cells&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="2" align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Combinations of markers to study leucocyte<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a></td><td class="td" title="table-entry  " align="left" valign="top">5-fluorescence &#40;in a tube&#41;&#58;<br>FLAER CD157-PE CD45-PerCP CD64-APC CD10-APCH7 or FLAER CD157-PE CD45-PECy7 CD64-ECD CD10-PECy5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">4-fluorescence &#40;2 in a tubes&#41;&#58;<br>FLAER CD157 &#40;or CD24&#41;-PE CD45-PerCP CD10-APC and FLAER CD157 &#40;or CD14&#41;-PE CD45-PerCP CD10-APC or FLAER CD157 &#40;or CD24&#41;-PE CD45-PECy7 CD10-PECy5<br>FLAER CD157 &#40;or CD14&#41;-PE CD45-PECy7 CD64-PECy5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Combination of markers to study red blood cells&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">CD235a-FITC&#44; CD59-PE &#40;clone of reference&#58; MEM43&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Tests&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Internal &#40;positive and negative populations or with different fluorescence intensity for each marker&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Indications&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Screening diagnostic&#59; monitoring of the disease and its treatment&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1393887.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Different combinations adapted to different flow cytometers&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Identification of deficient cells in <span class="elsevierStyleItalic">glucosyl phosphatidyl inositol</span> &#40;GPI&#41; by flow cytometry in diagnosis of PNH&#46;</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Population&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Initial phase&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Maintenance phase&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Adult patients</span> &#40;&#8805;<span class="elsevierStyleItalic">18 years old&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">600<span class="elsevierStyleHsp" style=""></span>mg per week<span class="elsevierStyleHsp" style=""></span>&#215;<span class="elsevierStyleHsp" style=""></span>4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">900<span class="elsevierStyleHsp" style=""></span>mg in the 5th week&#59; then 900<span class="elsevierStyleHsp" style=""></span>mg every 14<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>2 days&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="3" align="left" valign="top"><span class="elsevierStyleItalic">Paediatric patients with body weight</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>30&#8211;&#60;40<span class="elsevierStyleHsp" style=""></span>kg&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">600<span class="elsevierStyleHsp" style=""></span>mg per week<span class="elsevierStyleHsp" style=""></span>&#215;<span class="elsevierStyleHsp" style=""></span>2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">900<span class="elsevierStyleHsp" style=""></span>mg in the 3rd week&#59; then 900<span class="elsevierStyleHsp" style=""></span>mg every two weeks&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>20&#8211;&#60;30<span class="elsevierStyleHsp" style=""></span>kg&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">600<span class="elsevierStyleHsp" style=""></span>mg per week<span class="elsevierStyleHsp" style=""></span>&#215;<span class="elsevierStyleHsp" style=""></span>2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">600<span class="elsevierStyleHsp" style=""></span>mg in the 3rd week&#59; then 600<span class="elsevierStyleHsp" style=""></span>mg every two weeks&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>10&#8211;&#60;20<span class="elsevierStyleHsp" style=""></span>kg&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">600<span class="elsevierStyleHsp" style=""></span>mg per week<span class="elsevierStyleHsp" style=""></span>&#215;<span class="elsevierStyleHsp" style=""></span>1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">300<span class="elsevierStyleHsp" style=""></span>mg in the 2rd week&#59; then 300<span class="elsevierStyleHsp" style=""></span>mg every two weeks&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>5&#8211;&#60;10<span class="elsevierStyleHsp" style=""></span>kg&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">300<span class="elsevierStyleHsp" style=""></span>mg per week<span class="elsevierStyleHsp" style=""></span>&#215;<span class="elsevierStyleHsp" style=""></span>1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">300<span class="elsevierStyleHsp" style=""></span>mg in the 2nd week&#59; then 300<span class="elsevierStyleHsp" style=""></span>mg every three weeks&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1393886.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Dosage of eculizumab&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:26 [
            0 => array:3 [
              "identificador" => "bib0135"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Takeda"
                            1 => "T&#46; Miyata"
                            2 => "K&#46; Kawagoe"
                            3 => "Y&#46; Iida"
                            4 => "Y&#46; Endo"
                            5 => "T&#46; Fujita"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Cell"
                        "fecha" => "1993"
                        "volumen" => "73"
                        "paginaInicial" => "703"
                        "paginaFinal" => "711"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8500164"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0140"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Natural history of paroxysmal nocturnal hemoglobinuria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "P&#46; Hillmen"
                            1 => "S&#46;M&#46; Lewis"
                            2 => "M&#46; Bessler"
                            3 => "L&#46; Luzzatto"
                            4 => "J&#46;V&#46; Dacie"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJM199511093331904"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "1995"
                        "volumen" => "333"
                        "paginaInicial" => "1253"
                        "paginaFinal" => "1258"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7566002"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0145"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Diagnosis and management of paroxysmal nocturnal hemoglobinuria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Parker"
                            1 => "M&#46; Omine"
                            2 => "S&#46; Richards"
                            3 => "J&#46; Nishimura"
                            4 => "M&#46; Bessler"
                            5 => "R&#46; Ware"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2005-04-1717"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood"
                        "fecha" => "2005"
                        "volumen" => "106"
                        "paginaInicial" => "3699"
                        "paginaFinal" => "3709"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16051736"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "How I treat paroxysmal nocturnal hemoglobinuria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "Brodsky R&#46;A&#46; Brodsky"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2009-03-195966"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood"
                        "fecha" => "2009"
                        "volumen" => "113"
                        "paginaInicial" => "6522"
                        "paginaFinal" => "6527"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19372253"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0155"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin&#58; a novel mechanism of human disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "R&#46;P&#46; Rother"
                            1 => "L&#46; Bell"
                            2 => "P&#46; Hillmen"
                            3 => "M&#46;T&#46; Gladwin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jama.293.13.1653"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA"
                        "fecha" => "2005"
                        "volumen" => "293"
                        "paginaInicial" => "1653"
                        "paginaFinal" => "1662"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15811985"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0160"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "H&#46; Schrezenmeier"
                            1 => "P&#46; Muus"
                            2 => "G&#46; Socie"
                            3 => "J&#46; Szer"
                            4 => "A&#46; Urbano-Ispizua"
                            5 => "J&#46;P&#46; Maciejewski"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3324/haematol.2013.093161"
                      "Revista" => array:6 [
                        "tituloSerie" => "Haematologica"
                        "fecha" => "2014"
                        "volumen" => "99"
                        "paginaInicial" => "922"
                        "paginaFinal" => "929"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24488565"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0165"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria &#40;PNH&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "C&#46; Hall"
                            1 => "S&#46; Richards"
                            2 => "P&#46; Hillmen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2003-01-0009"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood"
                        "fecha" => "2003"
                        "volumen" => "102"
                        "paginaInicial" => "3587"
                        "paginaFinal" => "3591"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12893760"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0170"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46; Hillmen"
                            1 => "P&#46; Muus"
                            2 => "U&#46; Duhrsen"
                            3 => "A&#46;M&#46; Risitano"
                            4 => "J&#46; Schubert"
                            5 => "L&#46; Luzzatto"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2007-06-095646"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood"
                        "fecha" => "2007"
                        "volumen" => "110"
                        "paginaInicial" => "4123"
                        "paginaFinal" => "4128"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17702897"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0175"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "quiz 5105"
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Thrombosis in paroxysmal nocturnal hemoglobinuria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "A&#46; Hill"
                            1 => "R&#46;J&#46; Kelly"
                            2 => "P&#46; Hillmen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2012-09-311381"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood"
                        "fecha" => "2013"
                        "volumen" => "121"
                        "paginaInicial" => "4985"
                        "paginaFinal" => "4996"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23610373"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0180"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "K&#47;DOQI clinical practice guidelines for chronic kidney disease&#58; evaluation&#44; classification&#44; and stratification"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "National Kidney Foundation"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Kidney Dis"
                        "fecha" => "2002"
                        "volumen" => "39"
                        "paginaInicial" => "S1"
                        "paginaFinal" => "S266"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11904577"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0185"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "SEN-SEMFYC consensus document on chronic kidney disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46; Alcazar"
                            1 => "M&#46;I&#46; Egocheaga"
                            2 => "L&#46; Orte"
                            3 => "J&#46;M&#46; Lobos"
                            4 => "E&#46; Gonzalez Parra"
                            5 => "F&#46; Alvarez Guisasola"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Nefrologia"
                        "fecha" => "2008"
                        "volumen" => "28"
                        "paginaInicial" => "273"
                        "paginaFinal" => "282"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18590493"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0190"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46; Hillmen"
                            1 => "M&#46; Elebute"
                            2 => "R&#46; Kelly"
                            3 => "A&#46; Urbano-Ispizua"
                            4 => "A&#46; Hill"
                            5 => "R&#46;P&#46; Rother"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/ajh.21757"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Hematol"
                        "fecha" => "2010"
                        "volumen" => "85"
                        "paginaInicial" => "553"
                        "paginaFinal" => "559"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20658586"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0195"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46; Kelly"
                            1 => "L&#46; Arnold"
                            2 => "S&#46; Richards"
                            3 => "A&#46; Hill"
                            4 => "C&#46; Bomken"
                            5 => "J&#46; Hanley"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2141.2010.08099.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Haematol"
                        "fecha" => "2010"
                        "volumen" => "149"
                        "paginaInicial" => "446"
                        "paginaFinal" => "450"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20151973"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0200"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era&#58; the French experience"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; De Guibert"
                            1 => "R&#46; Peffault de Latour"
                            2 => "N&#46; Varoqueaux"
                            3 => "H&#46; Labussiere"
                            4 => "B&#46; Rio"
                            5 => "D&#46; Jaulmes"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3324/haematol.2010.037531"
                      "Revista" => array:6 [
                        "tituloSerie" => "Haematologica"
                        "fecha" => "2011"
                        "volumen" => "96"
                        "paginaInicial" => "1276"
                        "paginaFinal" => "1283"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21606169"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0205"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46; Hillmen"
                            1 => "C&#46; Hall"
                            2 => "J&#46;C&#46; Marsh"
                            3 => "M&#46; Elebute"
                            4 => "M&#46;P&#46; Bombara"
                            5 => "B&#46;E&#46; Petro"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa031688"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2004"
                        "volumen" => "350"
                        "paginaInicial" => "552"
                        "paginaFinal" => "559"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14762182"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0210"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46; Hillmen"
                            1 => "N&#46;S&#46; Young"
                            2 => "J&#46; Schubert"
                            3 => "R&#46;A&#46; Brodsky"
                            4 => "G&#46; Socie"
                            5 => "P&#46; Muus"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa061648"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2006"
                        "volumen" => "355"
                        "paginaInicial" => "1233"
                        "paginaFinal" => "1243"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16990386"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0215"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46;A&#46; Brodsky"
                            1 => "N&#46;S&#46; Young"
                            2 => "E&#46; Antonioli"
                            3 => "A&#46;M&#46; Risitano"
                            4 => "H&#46; Schrezenmeier"
                            5 => "J&#46; Schubert"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2007-06-094136"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood"
                        "fecha" => "2008"
                        "volumen" => "111"
                        "paginaInicial" => "1840"
                        "paginaFinal" => "1847"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18055865"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0220"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pregnancy in PNH&#58; another eculizumab baby"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46; Marasca"
                            1 => "V&#46; Coluccio"
                            2 => "R&#46; Santachiara"
                            3 => "G&#46; Leonardi"
                            4 => "G&#46; Torelli"
                            5 => "R&#46; Notaro"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2141.2010.08258.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Haematol"
                        "fecha" => "2010"
                        "volumen" => "150"
                        "paginaInicial" => "707"
                        "paginaFinal" => "708"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20553271"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0225"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Paroxysmal nocturnal hemoglobinuria &#40;PNH&#41; and pregnancy in the era of eculizumab"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "A&#46;V&#46; Danilov"
                            1 => "H&#46; Smith"
                            2 => "S&#46; Craigo"
                            3 => "D&#46;M&#46; Feeney"
                            4 => "V&#46; Relias"
                            5 => "K&#46;B&#46; Miller"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.leukres.2008.09.008"
                      "Revista" => array:6 [
                        "tituloSerie" => "Leuk Res"
                        "fecha" => "2009"
                        "volumen" => "33"
                        "paginaInicial" => "e4"
                        "paginaFinal" => "e5"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18952283"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0230"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46;J&#46; Kelly"
                            1 => "B&#46; Hochsmann"
                            2 => "J&#46; Szer"
                            3 => "A&#46; Kulasekararaj"
                            4 => "S&#46; de Guibert"
                            5 => "A&#46; Roth"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1502950"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2015"
                        "volumen" => "373"
                        "paginaInicial" => "1032"
                        "paginaFinal" => "1039"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26352814"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0235"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46; Hillmen"
                            1 => "P&#46; Muus"
                            2 => "A&#46; Roth"
                            3 => "M&#46;O&#46; Elebute"
                            4 => "A&#46;M&#46; Risitano"
                            5 => "H&#46; Schrezenmeier"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjh.12347"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Haematol"
                        "fecha" => "2013"
                        "volumen" => "162"
                        "paginaInicial" => "62"
                        "paginaFinal" => "73"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23617322"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0240"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria&#58; sustained efficacy and improved survival"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46;J&#46; Kelly"
                            1 => "A&#46; Hill"
                            2 => "L&#46;M&#46; Arnold"
                            3 => "G&#46;L&#46; Brooksbank"
                            4 => "S&#46;J&#46; Richards"
                            5 => "M&#46; Cullen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2011-02-333997"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood"
                        "fecha" => "2011"
                        "volumen" => "117"
                        "paginaInicial" => "6786"
                        "paginaFinal" => "6792"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21460245"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0245"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "&#91;Diagnosis and treatment of nocturnal paroxysmal hemoglobinuria&#93;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Urbano-Ispizua"
                            1 => "A&#46; Gaya"
                            2 => "E&#46; Colado"
                            3 => "M&#46; Lopez"
                            4 => "B&#46; Arrizabalaga"
                            5 => "V&#46; Vicente"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Med Clin &#40;Barc&#41;"
                        "fecha" => "2011"
                        "volumen" => "136"
                        "paginaInicial" => "121"
                        "paginaFinal" => "127"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0250"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Villegas A&#44; Arrizabalaga B&#44; Bonanad S&#44; Colado E&#44; Gaya A&#44; Gonz&#225;lez A&#44; et al&#46; Gu&#237;a cl&#237;nica HPN&#46; Consenso espa&#241;ol para diagn&#243;stico y tratamiento de Hemoglobinuria Parox&#237;stica Nocturna&#46; 2014 &#91;accessed May 2015&#93;&#46; Available from&#58; <a href="http://www.sehh.es/en/documents/guides-and-documents/2605-guias-de-consenso-sobre-diagnostico-y-tratamiento-de-la-hemoglobinuria-paroxistica-nocturna-hpn-actualizacion-2014.html">http&#58;&#47;&#47;www&#46;sehh&#46;es&#47;en&#47;documents&#47;guides-and-documents&#47;2605-guias-de-consenso-sobre-diagnostico-y-tratamiento-de-la-hemoglobinuria-paroxistica-nocturna-hpn-actualizacion-2014&#46;html</a>"
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0255"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;J&#46; Borowitz"
                            1 => "F&#46;E&#46; Craig"
                            2 => "J&#46;A&#46; Digiuseppe"
                            3 => "A&#46;J&#46; Illingworth"
                            4 => "W&#46; Rosse"
                            5 => "D&#46;R&#46; Sutherland"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/cyto.b.20525"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cytometry B Clin Cytom"
                        "fecha" => "2010"
                        "volumen" => "78"
                        "paginaInicial" => "211"
                        "paginaFinal" => "230"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20533382"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0260"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "High-sensitivity detection of PNH red blood cells&#44; red cell precursors&#44; and white blood cells"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "D&#46;R&#46; Sutherland"
                            1 => "A&#46; Illingworth"
                            2 => "M&#46; Keeney"
                            3 => "S&#46;J&#46; Richards"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Curr Protoc Cytom"
                        "fecha" => "2015"
                        "volumen" => "72"
                        "paginaInicial" => "6 37 1"
                        "paginaFinal" => "6629"
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
    "agradecimientos" => array:1 [
      0 => array:4 [
        "identificador" => "xack278018"
        "titulo" => "Acknowledgements"
        "texto" => "<p id="par0320" class="elsevierStylePara elsevierViewall">The authors would like to thank Alexion Pharma Espa&#241;a for its support in the development of the consensus statement&#46; Editorial services were provided by Ogilvy Healthworld Barcelona and funded by <span class="elsevierStyleGrantSponsor" id="gs1">Alexion Pharma Espa&#241;a</span>&#46;</p>"
        "vista" => "all"
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/23870206/0000014600000006/v3_201704140441/S2387020616301942/v3_201704140441/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "46796"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Consensus statement"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/23870206/0000014600000006/v3_201704140441/S2387020616301942/v3_201704140441/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020616301942?idApp=UINPBA00004N"
]